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ABSTRACT 
 
Colorectal cancer (CRC) is a worldwide health problem representing the 
third most commonly diagnosed cancer in males and the second in females, and 
the fourth leading cause of cancer mortality in the industrialized world. Due to its 
complexity, heterogeneous etiology and low cure rates of invasive disease, the 
early detection of the malignant phases and the prognostic assessment of this 
neoplasia remain crucial. Three main molecular pathways (CIN, MSI and CIMP) 
have been identified in CRC with specific genetic and epigenetic alterations that 
characterize each type of CRC.  
Recently, HOXB13 was found to be involved in hereditary predisposition to 
prostate cancer. Since the HOXB13 gene is normally expressed only in prostate 
and in distal colon, the main goal of this thesis was to assess the role of HOXB13 
in CRC. Specifically, we aimed to find out if somatic and eventually germline 
mutations existed in HOXB13 in a consecutive series of 67 colorectal 
adenocarcinomas with paired normal mucosa. Also, to evaluate and compare the 
mRNA and protein expression levels of this gene in tumor and adjacent normal 
tissue from different locations in the colon, and finally, to correlate the molecular 
findings with the clinicopathological data in CRC patients. 
 The findings show that, besides two described SNPs (rs9900627 and 
rs8556), no deleterious mutations were found in the coding region of HOXB13 in 
our series. Furthermore, HOXB13 was found to be downregulated in CRC tumors 
in comparison with normal mucosa, but this pattern was only seen in distal colon, 
as proximal colon exhibited an inverse pattern of expression. Overall, the protein 
levels of HOXB13 measured in 6 samples from proximal colon and in 5 samples 
from distal colon were not consistent with the respective levels of mRNA. Also, 
there were no associations between HOXB13 expression and the 
clinicopathological data of patients enrolled in the study.   
 This work allowed us to conclude that our series of CRC does not harbor 
deleterious HOXB13 mutations. In contrast to what was previously described, 
HOXB13 is also expressed in normal mucosa from proximal colon of CRC 
patients, but to a much lesser extent than in distal colon. Additionally, in distal 
colon, HOXB13 is downregulated in tumors comparing to normal mucosa, while in 
proximal colon, the reverse tendency was seen. Finally, the expression of HOXB13 
is independent of the clinicopathological data from the patients. 
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However, further studies are necessary in order to understand the 
mechanisms and molecular consequences behind HOXB13 downregulation in 
distal tumors, as well as its re-expression in proximal CRC. The possibility that 
opposite molecular changes involving the same gene may both confer selective 
advantage to colorectal cancer cells, depending on their location in the colon, is a 
very interesting scientific question worth to be studied further. 
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RESUMO 
 
O cancro colorectal (CRC) é visto, actualmente, como um problema de 
saúde a nível mundial e constitui a terceira neoplasia mais frequente em homens 
e a segunda em mulheres, assim como a quarta causa mais frequente de morte 
relacionada com cancro no mundo moderno. Devido á sua complexidade e 
heterogeneidade de factores etiológicos associados a reduzidas taxas de sucesso 
de cura de doença avançada, tanto a detecção precoce de estados malignos como 
a avaliação do prognóstico apresentam-se como pontos fulcrais. Foram descritas, 
até á data, três vias moleculares principais (CIN, MSI e CIMP) envolvendo 
alterações genéticas e epigenéticas especificas que caracterizam cada tipo de 
CRC. 
Recentemente, foi identificado o envolvimento do gene HOXB13 na 
predisposição hereditária para cancro da próstata. Sabendo que este gene 
apresenta expressão normal apenas na próstata e no cólon distal, o objectivo 
principal desta tese residiu em avaliar o papel do gene HOXB13 no CRC. Mais 
concretamente, este trabalho teve como objectivos a procura de mutações 
somáticas e germinativas numa série consecutiva de 67 adenocarcinomas 
colorectais, com a respectiva mucosa normal para cada caso; a avaliação e 
comparação dos níveis de expressão de mRNA e proteína de HOXB13 em tumores 
e tecido normal adjacente oriundo de diferentes áreas do cólon; e finalmente, a 
correlação dos dados de expressão com as variáveis clinicopatológicas dos 
doentes com CRC. 
Os nossos resultados mostraram que, para além de dois SNPs previamente 
descritos (rs9900627 e rs8556), não foram encontradas mutações deletérias na 
região codificante do gene HOXB13, na nossa série de amostras. Dados de 
expressão deste gene indicaram que a sua expressão esta diminuída em tumores 
em comparação com tecido normal, no entanto, este padrão foi apenas visível 
para amostras de cólon distal. As amostras de cólon proximal apresentaram um 
padrão inverso. De um modo geral, os níveis proteicos de HOXB13 avaliados em 
6 amostras de cólon proximal e 5 amostras de cólon distal, não estiveram de 
acordo com os respectivos níveis de expressão de mRNA. Adicionalmente, não se 
verificaram associações entre a expressão de HOXB13 e os dados 
clinicopatológicos dos doentes envolvidos no estudo. 
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Este trabalho permitiu-nos concluir quanto á ausência de mutações 
deletérias no gene HOXB13 na nossa serie de amostras. Contrariamente ao que 
foi previamente descrito, o gene HOXB13 é, também, expresso em mucosa 
normal de cólon proximal, apresentando, no entanto, uma expressão mais 
reduzida quando comparada com a de cólon distal. Neste, o gene HOXB13 
apresenta expressão reduzida em tumores quando comparado com mucosa 
normal, enquanto que a tendência inversa foi identificada nas amostras de cólon 
proximal. Por fim, concluímos que a expressão de HOXB13 é independente dos 
dados clinicopatológicos dos doentes com CRC. 
Contudo, estudos adicionais são necessários para uma melhor 
compreensão dos mecanismos e consequências moleculares adjacentes á 
diminuição de expressão do gene HOXB13 em tumores de cólon distal, assim 
como a sua re-expressão em tumores proximais. A possibilidade da existência de 
alterações moleculares, envolvendo o mesmo gene, que possam conferir 
vantagem selectiva a células neoplásicas colorectais, dependendo da sua 
localização no cólon, é uma questão científica deveras interessante, digna da 
formulação de estudos futuros. 
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I. INTRODUCTION 
 
1. Introducing colorectal cancer 
As a major health problem, cancer represents the leading cause of death in 
economically developed countries and the second leading cause of death in 
developing countries. Based on the GLOBOCAN 2008 estimates, about 12.7 
million cancer cases and 7.6 million cancer deaths are estimated to have occurred 
worldwide. This problem is a growing issue as its incidence continues to increase, 
not only due to the aging and growth of the world population but also because of 
an increasing adoption of cancer related behaviors, particularly smoking (Jemal et 
al., 2011).  Cancer arises as a result of changes occurring in the DNA sequence of 
cancer cells genome, which in turn leads to dysregulation of cellular pathways, 
disturbing its normal growth and proliferation. (Ponder, 2001; Stratton et al., 
2009). It is a heterogeneous condition, encompassing more than 100 distinct 
diseases with diverse risk factors and epidemiology.  
 The role of HOXB13 gene in colorectal cancer 
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Colorectal cancer (CRC) is a complex disease with a miscellaneous etiology, 
caused by a combination of various factors with environmental, genetic and 
epigenetic origins. In fact, CRC is generally viewed not as a single disease, but 
rather, a group of diseases, each with a different profile that is unlikely to be 
exactly recapitulated by any other. Although most CRC cases are sporadic, 
inherited cancer syndromes account for up to 5% of all cases (Gryfe, 2009). In 
addition, there are a number of cases in which a family history does not follow a 
classical Mendelian pattern, presumably because of incomplete penetrance 
and/or multifactorial effects (Figure 1) (Ilyas et al., 1999). 
 
 
 
 
 
 
 
 
 
 
 
 Exposure to specific environmental factors leads to alterations of the 
normal colonic mucosa that may give rise to a number of different diseases, 
including cancer. Typically, CRC develops from apparently normal mucosa into a 
benign precursor stage, the premalignant polyp, which then, can progress to 
carcinoma. The growth of colorectal cancer is clearly the result of a multi-step 
process that spans approximately 10-15 years. It is characterized by an 
accumulation of genetic and epigenetic alterations, leading to an invasive state  
(Worthley et al., 2007; Markowitz and Bertagnolli, 2009; Berg and Soreide, 2011) 
with metastasis appearing, usually, first in the liver and then in the lungs (Weiss 
et al., 1986). Different patterns of alterations cause different types of CRC with 
Figure 1- Cicle graph depicting the genotypic and phenotypic heterogeneity in CRC [adapted 
from (Lynch et al., 2009)]. 
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different characteristics that will be further described. In the western population 
the cumulative risk for developing CRC is 5-6%. Most colorectal carcinomas are 
located in the sigmoid colon and rectum, but there is evidence of a change in 
distribution in recent years, with an increasing proportion of more proximal 
carcinomas (Cucino et al., 2002; Caldarella et al., 2013). 
 
1.1 Epidemiology 
CRC is an important public health problem, representing the fourth leading 
cause of cancer mortality in the industrialized world. It is the third most 
commonly diagnosed cancer in males and the second in females, with more than 
1.2 million new cases and 608,700 deaths estimated worldwide for both sexes 
(Figure 2) (Jemal et al., 2011). 
 
 
 
 
 
 
 
 
 
 
 
In fact, comparing both sexes, incidence and mortality estimated rates are 
substantially higher in males (1.4:1), with an estimate of 663,600 new cases and 
320,600 deaths, than in females, with approximately 570,100 new diagnoses and 
288,100 deaths, in 2008 (Ferlay et al., 2010; Jemal et al., 2011). The highest 
incidence rates of CRC are found in newly economically developed areas, such as 
Australia, New Zealand, Europe and North America.  It was seen that these rates 
Figure 2- Estimated new cancer cases and deaths worldwide in 2008 [adapted from (Jemal et al., 
2011)]. 
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are rapidly increasing in several areas historically at low risk, such as in Spain and 
countries within Eastern Asia and Eastern Europe. These evidences have been 
reported also in the past (Center et al., 2009), and a possible explanation for this 
trend may be the adoption, by these countries, of risk factors associated with 
“Westernization” such as obesity and physical inactivity. In contrast, the lowest 
incidence rates for colorectal cancer are observed in Africa and South-Central 
Asia. The United States are the only country with significantly decreasing 
incidence rates in both sexes in the most recent time period (1975-2006), which 
may reflect the role of early detection of the disease and removal of precancerous 
lesions through screening techniques (Jemal et al., 2011). 
In Europe, incidence and mortality rates of CRC are very similar to those 
that characterize its worldwide distribution. The main difference, however, is that 
in Europe, CRC is considered the third cause of cancer-related death, accounting 
for 212,219 deaths in both sexes (Jemal et al., 2011). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In Portugal, differences in both incidence and mortality rates of this 
disease have been changing over the past few years. According to Pinheiro et al. 
(2003), in the year 2000 CRC was the most common cancer in men and the 
Figure 3- Estimated age-standardised incidence and mortality rates of CRC for men and 
women, in Portugal [Globocan, 2010 (IARC, 2010)]. 
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second most common in women, with 5,714 new cases of the disease estimated 
that year, for both sexes (Pinheiro et al., 2003). However, recent data points CRC 
as the third most common type of cancer in both sexes, with 6,952 new cases, 
being responsible for 3,691 deaths (Figure 3) (IARC, 2010). 
 
 
1.2 Etiologic factors 
Multiple dietary and lifestyle factors are known to be related to an 
increased risk of developing CRC (Giovannucci, 2002; Norat et al., 2002; 
Zhivotovskiy et al., 2012). Moreover, data from migrant studies showed the 
influence of environmental conditions as immigrants from populations with low 
CRC incidence tend to match the lifetime incidence characteristics of the new 
country of residence (McCredie et al., 1999). Several epidemiological studies have 
suggested that diet, physical activity, obesity, tobacco use, alcohol consumption, 
diabetes and the presence of inflammatory bowel diseases (IBDs) play an 
important role in the etiology of the disease (Hsing et al., 1998; Terry et al., 
2001; Giovannucci, 2002; Huxley et al., 2009; Zhivotovskiy et al., 2012). In fact, 
it was suggested that nearly 66-77% of CRC might be preventable by an 
appropriate combination of diet, physical activity and a healthy lifestyle (Platz et 
al., 2000; Giovannucci, 2002). 
Obesity and the type of diet, namely the consumption of red and processed 
meat, have been associated with an increased risk of the development of the 
disease, but the reasons leading to this association are not clear (Giovannucci, 
2002; Huxley et al., 2009). A possible explanation relies on the fact that red meat 
is a major source of total and saturated fat, proteins and carcinogens like 
heterocyclic amines resulting from frying and grilling. Thus, the digestion of 
these substances might lead to the initiation of carcinogenic pathways (Norat et 
al., 2002). On the other hand, the role of fibers through intake of vegetables, 
fruits and other sources has been controversial over the years. In the past it was 
suggested that the consumption of foods with high fiber content was associated 
with a lower CRC risk (Macquart-Moulin et al., 1986; Kune and Kune, 1987; Trock 
et al., 1990). More recent studies, however, presented null results when fiber 
intake and CRC incidence were associated (Fuchs et al., 1999; Schatzkin et al., 
2000; Michels et al., 2005). Whereas obesity increases risk, physical activity is 
 The role of HOXB13 gene in colorectal cancer 
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associated with its decrease, with a stronger inverse association observed for 
colon cancer than for rectal cancer (Giovannucci, 2002; Huxley et al., 2009).  
Associated with obesity and physical inactivity, insulin resistance and, 
consequently, hyperinsulinemia have also been described as risk factors for CRC 
(Giovannucci, 2002). Several studies have found type 2 diabetes mellitus 
(associated with insulin resistance) (Hu et al., 1999; Larsson et al., 2005), 
hyperinsulinemia (excess of circulating insulin in the blood) (Schoen et al., 1999) 
and high concentrations of insulin-like growth factors (IGFs) (Jenkins et al., 1997) 
to be directly associated with CRC, years before the onset of the disease. 
Up until recently, tobacco was not generally implicated as a cause of CRC  
due to the lack of conclusions in short term studies in which the effects of long 
exposure to the carcinogenic agents of the tobacco could not be assessed. Yet, 
several publications in which an induction period of three to four decades could 
be accounted for, led to strong conclusions regarding a positive effect of tobacco 
use in the risk of developing CRC (Heineman et al., 1994; Le Marchand et al., 
1997; Hsing et al., 1998). In fact, studies conducted by Huxley et al. (2009), 
indicated that smokers had a 16% greater risk, compared to people who have 
never smoked. The carcinogenic effect of tobacco may be due to the formation of 
DNA adducts in the colon mucosa, as an effect of polycyclic hydrocarbons present 
in cigarettes. In this same study, the relation between the effect of alcohol 
consumption and the risk of CRC development indicated that alcohol is a strong 
dose-response risk factor, pointing out a 60% greater risk of developing the 
disease in heavy drinkers when compared to light or nondrinkers (Huxley et al., 
2009).  
There is also an increased risk of tumor development in patients with 
chronic inflammatory diseases of the large bowel, such as ulcerative colitis (UC) 
and colonic Crohn’s disease, depicting the well-known association between 
inflammation and the development of cancer (Ilyas et al., 1999). Thus, this risk 
increases with longer duration and greater anatomic extent of colitis, the 
presence of primary sclerosing cholangitis, family history of CRC and degree of 
inflammation (Xie and Itzkowitz, 2008). 
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1.3 Anatomy and functionality of the large intestine 
For homeostasis to occur in the human organism, food must be broken 
down into forms that can be absorbed and used by body cells. This process, 
called digestion, takes place in the digestive system which comprises the 
gastrointestinal (GI) tract and the accessory digestive organs. 
 Located in the final portion of the GI tract, with about 1.5m long and 
6.5cm in diameter, the large intestine extends from the ileous to the anus, and 
comprehends four different structures: the cecum, the colon which is divided into 
ascending, transverse, descending, and sigmoid portions, the rectum, and anal 
canal (Figure 4). In this area, mechanical and chemical digestion occurs, and for 
that, specialized cells are present in the wall of the mucosa responsible for the 
absorption of water, ions, vitamins and the production of mucus (Tortora and 
Derrickson, 2012).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4- Simplified illustration of the digestive system (left) and view of the final portion of 
the GI tract depicting the large intestine (right) [adapted from (Tortora and Derrickson, 2012)]. 
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1.4 Histopathology and staging 
The type of colorectal tumor describes the cells from which the tumor 
arises. Typically, they may be divided into epithelial and non-epithelial. The first 
group encompasses the adenomas, carcinomas and carcinoid tumors, whilst the 
second group includes the malignant lymphomas and gastrointestinal stromal 
tumors (GISTs) (Hamilton and Aaltonen, 2000). 
Most colorectal carcinomas are gland-forming with variations in size and 
conformation of the glandular structures, and may be divided into several types 
according to these aspects (Table 1). Adenocarcinoma is the most common type 
of colorectal carcinoma (nearly 85%) and 10-15% are commonly diagnosed as 
mucinous adenocarcinoma. The other tumor types present a much lower 
incidence (Lanza et al., 2011). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 For most histologic types of CRC there is no clear stage-independent 
prognostic significance, although it was suggested that rare types such as signet-
ring cell carcinoma and small-cell carcinoma are prognostically unfavorable, 
whereas the medullary carcinoma presents a better prognosis (Compton, 2003). 
Also, an association with the microsatellite instability (MSI) pathway was found 
mostly in the medullary carcinoma, and the mucinous carcinoma (Hamilton and 
Aaltonen, 2000). It has also been described that mucinous carcinomas are evenly 
distributed in the left and right colon and that in comparison to other types, 
exhibit a high frequency of CpG island methylator phenotype (CIMP) and rare 
Adenocarcinoma 
Medullary carcinoma 
Mucinous adenocarcinoma 
Signet-ring cell carcinoma 
Squamous cell carcinoma 
Adenosquamous carcinoma 
Small-cell carcinoma 
Undifferentiated carcinoma 
Table 1- Histological classification of colorectal tumors according to the World Health 
Organization (WHO) [adapted from (Hamilton and Aaltonen, 2000)]. 
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TP53 mutations, suggesting that these tumors represent a distinct pathologic 
entity (Jass, 2007). The MSI and CIMP pathways will be further described. 
When managing CRC, pathologic tumor staging assessment remains a 
crucial step for prognostic evaluation and treatment decision. The most 
commonly used system for CRC staging is the TNM system. Others, although less 
precise, are still used such as the Astler-Coller and Dukes systems (Centelles, 
2012; Shia et al., 2012). According to the American Joint Committee on Cancer 
(AJCC), the three letters of the TNM system, have a specific meaning according to 
the characteristics of the tumor: T describes the extent of growth of the primary 
tumor into the wall of the intestine and whether it has grown into nearby areas; N 
indicates the extent of spread of the disease to regional lymph nodes; and M 
informs if the cancer has spread to other organs of the body, thus indicating the 
presence or absence of distant metastasis. These three letters are combined with 
numbers in order to indicate increasing severity and progression of the disease 
(Table 2) (Edge et al., 2010). After combining the information of  each letter, the 
stage can be assessed in a process called stage grouping in which the stage is 
expressed in Roman numerals from I to IV (Centelles, 2012). 
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Primary tumor (T) 
TX Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
Tis Carcinoma in situ: intraepithelial or invasion of lamina propria 
T1 Tumor invades submucosa 
T2 Tumor invades muscularis propria 
T3 Tumor invades muscularis propria into pericolorectal tissues 
T4a Tumor penetrates to the surface of the visceral peritoneum 
T4b Tumor directly invades or is adherent to other organs or structures 
Regional lymph nodes (N) 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in 1-3 regional lymph nodes 
N1a Metastasis in 1 regional lymph node 
N1b Metastasis in 2-3 regional lymph nodes 
N1c 
Tumor deposit(s) in the subserosa, mesentery, or nonperitonealized 
pericolic or perirectal tissues without regional nodal metastasis 
N2 Metastasis in 4 or more regional lymph nodes 
N2a Metastasis in 4-6 or more regional lymph nodes 
N2b Metastasis in 7 or more regional lymph nodes 
Distant metastasis (M) 
M0 
No distant metastasis (no pathologic M0; use clinical M to complete 
stage group) 
M1 Distant metastasis 
M1a 
Metastasis confined to 1 organ or site (eg liver, lung, ovary, nonregional 
node) 
M1b Metastases in more than 1 organ/site or the peritoneum 
 
 
After the diagnosis of the disease is established, the stage may be 
assessed before initiation of preoperative adjuvant treatment - clinical staging, 
cTNM - or after surgical resection and examination of the resected specimen - 
pathologic staging, pTNM. For patients who were given a clinical stage in the first 
Table 2 - Overview of the American  Joint Committee on Cancer (AJCC) TNM cancer staging 
system for colorectal carcinomas [adapted from (Shia et al., 2012)]. 
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place, a modified pathologic stage is evaluated after surgical resection adding a 
“y” to the acronym (ypTNM). Clinical staging is based on medical history, physical 
examination along with sigmoidoscopy and colonoscopy with biopsy (Shia et al., 
2012). 
 Additionally, examinations such as computed tomography (CT), magnetic 
resonance imaging (MRI) and positron emission tomography (PET) are used to 
evaluate presence or absence of metastasis. For patients with rectal cancer 
endoscopic ultrasound (EUS) with or without fine-needle aspiration of lymph 
nodes may also be used (Edge et al., 2010). 
 
 
1.5 Screening and diagnosis 
The first step in the assessment of the diagnosis of CRC must consist in 
the application of screening techniques. The goal of cancer screening is to reduce 
mortality by reducing the incidence of advanced disease. Modern CRC screening 
can achieve this by detecting early-stage adenocarcinomas and removal of 
adenomatous polyps after identification. In fact, it is estimated that nearly 60% of 
CRC deaths could be prevented if population with 50 years or older were 
screened routinely (He and Efron, 2011).  
There is a range of options for CRC screening in the average-risk 
population, with current technology dividing into two different categories: the 
stool tests, which are best suited for the detection of cancer, although some 
information about advanced adenomas can also be delivered, and the structural 
exams that can achieve the duality of detecting, both adenocarcinoma and 
adenomatous polyps. The former tests include the fecal occult blood test (FOBT), 
fecal immunochemical test (FIT) and fecal DNA testing (sDNA), while the latter 
comprises flexible sigmoidoscopy (FSIG), colonoscopy (CSPY), double-contrast 
barium enema (DCBE) and computed tomographic colonography (CTC) (Levin et 
al., 2008; Cummings and Cooper, 2011). For individuals at average risk, there are 
specific guidelines for CRC screening (Table 3).  
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Tests that detect adenomatous polyps and cancer 
FSIG every 5 years, or 
CSPY every 10 years, or 
DCBE every 5 years, or 
CTC every 5 years 
Tests that primarily detect cancer 
Annual FOBT with high test sensitivity for cancer, or 
Annual FIT with high test sensitivity for cancer, or 
sDNA, with high sensitivity for cancer, interval uncertain 
 
 
The choice of a test, however, is dependent on many factors including 
patient´s economic situation, as well as the physician’s standpoint. There are 
also specific screening guidelines for individuals at an increased risk of 
developing CRC summarized in Table 4 specifically regarding the familial and 
inherited risk only (Winawer et al., 2003).  For individuals to be considered in this 
group, they must exhibit, at least one of the following criteria:  history of 
adenomatous polyps; a personal history of curative-intent resection of CRC; a 
family history of CRC or colorectal adenomas diagnosed in a first degree relative, 
before the age of 60 years; a history of inflammatory bowel disease, or the 
presence of a known hereditary syndrome (Levin et al., 2008). After the onset of 
the symptomatology of the disease, comes the need to confirm its diagnosis. A 
wide variety of abdominal symptoms and signs are consistent with CRC, such as 
rectal bleeding, blood in the stool, abdominal pain, change in bowel habits, 
nausea, vomiting, distention, weight loss, fatigue, and anemia. However, these 
are nonspecific and somewhat dependent on the location of the tumor and the 
extent of constriction of the lumen caused by the cancer (Majumdar et al., 1999). 
Table 3- Screening guidelines for the early detection of CRC and adenomas for men and 
women aged 50 years or older [adapted from (Levin et al., 2008)]. 
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Familial risk category Screening recommendations 
 
First-degree relative affected with 
colorectal cancer or an adenomatous polyp at 
age ≥ 60 years, or 2 second-degree relatives 
affected with CRC. 
 
Same as average risk but starting at 
age 40 age 
 
Two or more first-degree relativesa with 
colon cancer, or a single first-degree relative 
with colon cancer or adenomatous polyps 
diagnosed at an age <60 years 
CSPY every 5 years, beginning at age 
40 years or 10 years younger than the 
earliest diagnosis in the family, whichever 
comes first 
One second-degree or any third-degree 
relativeb,c  with CRC 
Same as average risk 
Gene carrier or at risk for familial 
adenomatous polyposisd 
FSIG annually, beginning at age 10 – 
12 yearse 
Gene carrier or at risk for HNPCC 
 
CSPY, every 1 – 2 years, beginning at 
age 20 – 25 years or 10 years younger 
than the earliest case in the family, 
whichever comes first 
 
a First-degree relatives include patients, siblings, and children. 
b Second-degree relatives include grandparents, aunts, and uncles. 
c Third-degree relatives include great-grandparents and cousins. 
d In FAP, CSPY should be used instead of FSIG because of the preponderance of proximal 
colonic adenomas. CSPY screening in AAPC should probably begin in the late teens or early 
20s. 
 
The fact that most of these symptoms are more often caused by conditions 
other than CRC (infection, hemorrhoids, inflammatory bowel disease), associated 
with the fact that most patients with early CRC are asymptomatic, hampers the 
diagnosis of this malignancy (Hamilton and Aaltonen, 2000; Rosenberg et al., 
2005). The techniques used for CRC screening are roughly the ones used for its 
diagnosis, with CSPY displaying an essential role. Using this methodology, a 
biopsy of the tumor can be made allowing, at the same time, to verify the entire 
colon for the presence of polyps or other cancers. To evaluate the presence and 
extent of metastases, particularly in the liver, a physical examination combined 
with chest x-ray, liver function tests, carcinoembryonic antigen (CEA) level, CT 
combined with fluorodeoxyglucose-positron emission tomography (FDG-PET) or 
MRI are, currently, the best options (Townsend, 2007; Van Cutsem et al., 2010). 
 
Table 4-CRC screening recommendations for people with familial or inherited risk [adapted from 
(Winawer, 2003)]. 
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1.6 Treatment of CRC 
The choice of the strategy for CRC treatment depends mostly on the stage 
and mutational status of the tumor. Surgery remains the most common treatment 
for CRC and it is recommended, whenever is possible, for all stages of the disease 
due to its curative intent (Boland et al., 2000). When treating an early stage 
localized disease, surgery has a greater chance of cure, however, 20-25% of 
patients have metastases at the time of diagnosis, and approximately 50-60% of 
the remainder, will develop metastases, contributing to the high mortality rates of 
CRC registered every year (Van Cutsem et al., 2010). Systemic therapy is, 
currently, the mainstay of management for most patients with metastatic 
colorectal cancer (mCRC), providing a more palliative than curative treatment. 
Even so, in a small proportion of these cases, surgical resection of metastases can 
be achieved after systemic therapy, which decreases the size of metastases to 
render the surgery possible (Edwards et al., 2012). Systemic treatment of mCRC, 
or chemotherapy, makes use of four active cytotoxic drugs (5-fluorouracil (5-FU), 
irinotecan, oxaliplatin and capecitabine) and three biological agents 
(bevacizumab, cetuximab and panitumumab) that are used in combination, or as 
single agents.  
The chemotherapy options currently used are the FOLFOX regimen 
(leucovorin, 5-FU and oxaliplatin), the FOLFIRI regimen (leucovorin, 5-FU and 
irinotecan) and the CAPOX regimen (capecitabine and oxaliplatin) which have 
shown a similar activity and efficacy as first-line treatments for mCRC, however, 
with a different toxicity profile. Leucovorin is a complement that promotes 5-FU 
activation, thereby enhancing its ability to bind to its target – thymidylate 
synthase. The recently added monoclonal antibodies bevacizumab, cetuximab 
and panitumumab are agents that act in two central cellular molecules: the 
vascular endothelial growth factor (VEGF) and the epidermal growth factor 
receptor (EGFR), respectively. Their benefit was rapidly seen in combination with 
the chemotherapy already in use and, because of that, are now used as first-line 
therapy in combination with standard chemotherapy (Saltz et al., 2008; Van 
Cutsem et al., 2009; Douillard et al., 2010). 
Specifically for rectal cancer, radiotherapy and 5-FU adjuvant or neo-
adjuvant based therapy are currently the most accepted options for stage II and III 
of the disease (Van Cutsem et al., 2010). 
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2. Colorectal carcinogenesis 
Colorectal carcinogenesis requires a normal cell to accumulate multiple 
genetic and epigenetic alterations, and establish successive clones, each 
characterized by a growth advantage. This can be achieved either by an increased 
rate of proliferation, impaired apoptosis, or both cellular events (Worthley et al., 
2007). The adenoma-carcinoma sequence model was initially proposed by Fearon 
and Vogelstein, who suggested that colorectal carcinogenesis is a result of a 
group of four premises: i) the activation of oncogenes, and/or inactivation of 
tumor suppressor genes; ii) the formation of a malignant tumor requires the 
occurrence of mutations in at least four to five genes (whereas fewer changes 
suffice for benign phenotype); iii) the total accumulation of changes (rather than 
their order of occurrence) defines the tumor’s biologic behavior; iv) in some 
cases, mutant suppressor genes exert a phenotypic effect, even in the 
heterozygous state, which may point to the idea that some tumor suppressor 
genes may not be “recessive” at the cellular level (Vogelstein, 1990). However, 
only 5% of adenomas progress to carcinoma. Additionally, this model (Figure 5) 
highlights the inactivation of APC gene as the initiating event of colorectal 
carcinogenesis, leading to the formation of adenomas from normal colonic 
mucosa. This is followed by mutations in KRAS gene, which promotes 
adenomatous growth, allelic loss of chromosome 18q and inactivation of deleted 
in colorectal cancer (DCC) and SMAD4 genes, both involved in the transforming 
growth factor (TGF)-β pathway. The transition from late adenoma to carcinoma is 
mediated by inactivation of TP53 and loss of heterozygosity (LOH) of 
chromosome 17p (Vogelstein, 1990; Worthley et al., 2007; Markowitz and 
Bertagnolli, 2009; Soreide et al., 2009; Berg and Soreide, 2011).  
 
 
 
 
 
 
Figure 5- The different steps of the adenoma-carcinoma sequence with depiction of the main 
alterations that characterize each stage [adapted from (Townsend, 2007)]. 
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The recent advances in the area of cancer research have led to a better 
understanding of the roles of the different genes and pathways involved in 
colorectal carcinogenesis, which in turn led to the need to include new findings in 
the classical pathway. Currently, colorectal carcinogenesis is viewed as an 
imbalance between mutation development and the mechanisms responsible for 
cell cycle maintenance. When the cell cycle is no longer capable of controlling the 
mutation rate, it is referred as “genomic instability”. Three main pathways, rather 
than a specific sequence of events, have been identified that contribute to this 
state: chromosomal instability (CIN), microsatellite instability (MSI), and CpG 
island methylator phenotype (CIMP). (Worthley et al., 2007; Markowitz and 
Bertagnolli, 2009; Berg and Soreide, 2011; Perea et al., 2011; Kanthan et al., 
2012). The grouping of patients in the different pathways, based on the 
molecular events of the tumors, facilitate the prediction of prognosis, the 
response or resistance to the therapy and the possible etiological factors that 
may help to prevent the disease (Kanthan et al., 2012). 
 
2.1 Chromosomal instability (CIN) pathway 
As already stated, for a cancer to arise, genomic instability is a central 
step. In CRC, its main cause is CIN (Markowitz and Bertagnolli, 2009; Perea et al., 
2011). The CIN, or “suppressor”, pathway accounts for nearly 70-85% of CRCs and 
it is characterized by gain or loss of whole chromosomes or chromosomal 
regions, but also by translocations harboring genes involved in the process of 
colorectal carcinogenesis (Al-Sohaily et al., 2012). As a result, aneuploidy, 
chromosomal amplifications and a high frequency of LOH are characteristics of 
this type of tumors. Causes leading to CIN are currently still unknown, but it was 
suggested that these may be related to defects in chromosome segregation, 
telomere dysfunction or defects in the DNA repair mechanisms. Some of the main 
karyotypic alterations present in CIN pathway are amplifications on chromosomes 
7, 8q and 13q, deletions on chromosomes 1, 4, 5, 8q, 18q and 17p, which 
contains TP53 gene, and focal gains or losses in regions containing important 
cancer genes such as VEGF, MYC and PTEN (Sheffer et al., 2009). Coupled with 
these abnormalities, there is also the accumulation of mutations in oncogenes 
and tumor suppressor genes for example in KRAS and adenomatous polyposis 
coli (APC) genes. Nonetheless, only a minority of CRCs characterized by this 
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pathway have a full complement of these molecular abnormalities. Other genetic 
events might overlap or bypass these steps, in order to deliver the necessary 
biological characteristics of the tumor (Worthley et al., 2007; Markowitz and 
Bertagnolli, 2009). 
 
2.1.1 The APC gene  
Of all the events in colorectal carcinogenesis, Wnt pathway activation is 
considered the initial event in this cancer (Berg and Soreide, 2011). This signaling 
pathway occurs when the oncoprotein β-catenin binds to nuclear partners and 
creates a transcription factor that regulates genes involved in cellular activation 
(Goss and Groden, 2000; Markowitz and Bertagnolli, 2009). The levels of β-
catenin are regulated by a degradation complex which breaks β-catenin and 
inhibits its nuclear localization, therefore controlling its action. Located on 
chromosome 5q21, the tumor suppressor gene APC encodes a protein with 
multiple functional domains, which is a very important component of this 
complex (Worthley et al., 2007; Al-Sohaily et al., 2012). The most common 
mutation in CRC occurs in the APC gene, most often in the rectum, resulting in a 
truncated form of the protein. Inactivation of APC causes Wnt signaling to be 
inappropriately and constitutively activated (Figure 6). As a result, there is an 
accumulation of cytoplasmatic β-catenin which, then, binds to the TCF 
transcription factors affecting important cellular mechanism such as proliferation, 
differentiation, migration and apoptosis through transcriptional activation of c-
MYC, Cyclin D1, MMP7, among others. In most sporadic colorectal adenomas and 
cancers, both copies of APC are inactivated by somatic mutations and deletions 
(Galiatsatos and Foulkes, 2006; Markowitz and Bertagnolli, 2009).  
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2.1.2 The KRAS gene  
The KRAS gene encodes a GTP-binding protein involved in signal 
transduction present in many molecular pathways, which is activated in response 
to extracellular signals. When mutated (mainly in codons 12 and 13 of exon 2) it 
constitutively activates the mitogen-activated protein kinase (MAPK) signaling 
pathway, which controls cellular growth, differentiation, survival, apoptosis, cell 
motility and proliferation (Markowitz and Bertagnolli, 2009). Mutations in the 
KRAS proto-oncogene are an early event in malignant transformation and appear 
in approximately 30-60% of the CRCs. It is proposed that these mutations may be 
of importance in the transition from adenoma to carcinoma through activation of 
downstream targets including BCL-2, E2F4 and MMP1. However, although these 
mutations in KRAS confer a growth advantage to its daughter cells, they are 
neither sufficient nor necessary to drive carcinogenesis (Worthley et al., 2007; Al-
Sohaily et al., 2012). Furthermore, KRAS mutations status is considered a 
predictive factor in response to anti-EGFR therapy. When a mutation is present, 
KRAS and its downstream effectors become independent of EGFR, rendering the 
therapy ineffective. On the other hand, tumors with wild-type KRAS, will benefit 
from an anti-EGFR therapy as their EGFR-KRAS signaling axis is functioning and 
can, thus, be inhibited (Cartwright, 2012; Edwards et al., 2012; Arends, 2013). 
However, only 30% of patients with wild-type KRAS respond to anti-EGFR therapy 
as other mutations particularly in other genes of the RAS family (NRAS, HRAS) and 
BRAF might provide an alternative mechanism for activation of this pathway.  
 
Figure 6- Wnt signaling pathway 
in the presence of wild-type (A) 
and mutated APC (B) [adapted 
from (Cabrera and Lopez-Nevot, 
2005)]. 
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2.1.3 Loss of 18q (SMAD2, SMAD4 and DCC) 
The long arm of chromosome 18 contains many candidate tumor 
suppressor genes, including DCC, SMAD2 and SMAD4. Allelic loss at this site is 
detected in 50-70% of CRCs and is often associated with a poor prognosis in 
stage II and III of the disease. DCC encodes a transmembrane receptor of the 
immunoglobulin superfamily that promotes apoptosis, when its ligand, netrin-1, 
is absent (Al-Sohaily et al., 2012). SMAD2 and SMAD4 are transcription factors 
involved in TGF-β signaling pathway that regulate the transcription of key target 
genes, such as MYC, CBFA1, FLFR and furin (McDermott et al., 2002). 
 
2.1.4 Loss of TP53 
TP53 gene encodes a transcription factor with tumor suppressor activity, 
which activates a number of genes involved in cell cycle arrest, senescence, 
autophagy and apoptosis. When genetic damage occurs, DNA repair genes are 
activated in order to fix the problem. However, when the damage is too great for 
the cell to repair, TP53 induces pro-apoptotic genes (BBC3, noxA and BAX) leading 
to cell death. Due to that characteristic, TP53 is often called “guardian of the 
genome” (Mills, 2005; Arends, 2013). Mutations or loss of TP53, usually through 
allelic loss of 17p, are observed in 50%-75% of CRC (Worthley et al., 2007). This is 
often a late event in the CIN pathway, and associated with the fact that the 
frequency of TP53 mutations increases relative to the histological stage of the 
lesion within the pathway, this strongly suggests an important role of this gene in 
the transition from pre-invasive to invasive disease (Berg and Soreide, 2011; Al-
Sohaily et al., 2012). 
 
2.2 Microsatellite instability (MSI) pathway  
The MSI, or “mutator”, pathway is the other main mechanism for genomic 
instability in CRC (Worthley et al., 2007). Spread throughout the genome, there 
are short repeat nucleotide sequences that are prone to errors during replication, 
due to its repetitive nature. These sequences, named microsatellites, are present 
in both protein-coding and non-coding regions of the DNA. The DNA mismatch 
repair (MMR) system recognizes and repairs these errors during DNA replication. 
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Members of the MMR system identified so far include MLH1, MSH2, MSH6, PMS2, 
MLH3, MSH3, PMS1 and Exo1 and, together, they form a strand specific protein 
complex responsible for the repairing of DNA errors (Al-Sohaily et al., 2012). 
However, if an abnormality is present in the genes encoding  the proteins that are 
part of this system, these errors will not be repaired, which may lead to MSI 
ultimately leading to gene inactivation in specific areas such as in TGFβR2, EGFR 
and BAX genes, contributing to the development and progression of CRC (Perea et 
al., 2011). The location and frequency of these errors in the genome confer 
different characteristics to MSI tumors. In order to provide uniformity of definition 
of MSI tumors, and to aid clinicopathological practice, a standardized panel of 
microsatellites was created (Boland et al., 1998). This panel includes five markers: 
two mononucleotide (BAT25 and BAT26) and three dinucleotide microsatellites 
(D5S346, D2S123 and D17S250). MSI-H (high) is defined by MSI in, at least, two 
markers, MSI-L (low) when MSI occurs in one site and microsatellite stable (MSS) 
when no instability is seen (Worthley et al., 2007; Kanthan et al., 2012). The term 
“MSI tumors” typically refers to MSI-H tumors and approximately 15% of all CRC 
cases exhibit this phenotype (Ward et al., 2001; Perea et al., 2011). This may 
emerge in two distinct ways: first, with germline mutations in MMR genes, as seen 
in Lynch syndrome, and secondly due to somatic mutations or acquired promoter 
hypermethylation, most often in the MLH1 gene, covering most sporadic cases. In 
fact, MSI-H sporadic tumors appear to be strongly related with methylation of 
MLH1 whilst MSI-L lesions may be more associated with MGMT methylation, KRAS 
mutation and low frequency of 5q LOH (Worthley et al., 2007). 
As seen in Figure 7, CIN and MSI tumors are considered mutually exclusive. 
In the latter, the mechanism of genomic instability is provided by MMR 
dysfunction without the need for CIN (Worthley et al., 2007; Perea et al., 2011). 
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2.3 CpG island methylator phenotype (CIMP) pathway   
The influence of epigenetics in CRC has long been considered and studied 
as a driving mechanism of carcinogenesis. Epigenetic alterations refer to changes 
in gene expression or function, without affecting the DNA sequence. In humans 
this is usually caused either by DNA methylation, histone modifications and 
miRNA interference (Wong et al., 2007). DNA methylation commonly occurs at 
specific sites called CpG islands. These regions contain high levels of cytosine-
guanine pairs with phosphate bonds present in the genome, making up 
approximately 40%-50% of gene promoters in mammals (Perea et al., 2011). In 
normal conditions, when a gene is expressed, these CpG sites are unmethylated, 
and when methylation occurs it may inhibit gene expression and result in gene 
inactivation. Specific promoter methylation occurs, physiologically, to silence 
particular genes, such as in X-chromosome inactivation, while decontrolled 
methylation may occur pathologically as an important step in carcinogenesis. In 
fact, the epigenetic silencing of a gene by CpG island methylation is considered 
biologically equivalent to acquiring an inactivating mutation and it may occur as 
the first, second, or both hits in silencing tumor suppressor genes (Worthley et 
Figure 7- Genetic instability pathways leading to CRC. The associations between the three major 
pathways of genetic instability (CIN, MSI and CIMP) in CRC are shown [adapted from (Markowitz and 
Bertagnolli, 2009)]. 
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al., 2007). In CRC, the influence of epigenetics is seen both by global 
hypomethylation of the genome and simultaneous hypermethylation of the 
promoter region of specific genes. This provides an alternative mechanism for 
loss of function of tumor suppressor genes such as p16, APC, MLH1 and MGMT  
(Kanthan et al., 2012). A mutation that activates the gene BRAF is thought to be 
the initial step of this pathway resulting in an inhibition of apoptosis in colonic 
epithelial cells. BRAF mutations are present in most CRCs with CIMP phenotype 
and those who do not exhibit a BRAF mutation, may have a mutation in KRAS. 
This is, generally, preceded by other alterations such as MLH1 promoter 
methylation that leads to MSI. It is, then, clear the association between the two 
carcinogenic pathways, MSI and CIMP. On the other hand, CIMP and CIN are two 
mutually exclusive carcinogenic pathways (Worthley et al., 2007; Markowitz and 
Bertagnolli, 2009; Berg and Soreide, 2011).  
CIMP tumors are classified as CIMP positive (10-20% of CRCs) or negative, 
relative to the methylation status of a significant proportion of specific genes 
(CACNA1G, IGF2, NEUROG1, RUNX3 and SOCS1) present in a panel proposed by 
Weisenberger and colleagues (Weisenberger et al., 2006). Clinically, CIMP positive 
tumors have a particularly poor prognosis (Worthley et al., 2007; Hagland et al., 
2013) and, similar to MSI tumors, are proximately located (Ogino et al., 2006) 
and associated with female sex, exhibit a poor degree of differentiation, high 
BRAF and low TP53 mutations (Toyota et al., 2000; Ogino and Goel, 2008).   
  
 
 
3. Familial history and the hereditary syndromes 
When assessing the total number of CRC cases, a distinction between what 
is truly hereditary and what is familial should be considered. The former 
implicates that a distinct genetic basis has been defined, whereas the latter 
comprises an increased predisposition to cancer, generally seen in members of 
the same family, but its causes may be multifactorial. In other words, in these 
cases it is not known whether there is a hereditary basis with possible inactivation 
of tumor suppressor genes in the germline, or whether this predisposition is 
stochastic. In that context, it is estimated that approximately 20%-30% of all CRC 
cases have a familial basis (Rustgi, 2007). Albeit there has been an effort to study 
the familial weight in CRC (Wiesner et al., 2003), further studies are necessary for 
a better understanding of the causes behind this relatively large subset of CRCs. 
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Hereditary CRC syndromes arise as a result of germline mutations in 
specific genes involved in colorectal carcinogenesis. The most common 
syndromes identified so far are familial adenomatous polyposis (FAP), MUTYH-
associated polyposis (MAP), Lynch syndrome or hereditary nonpoliposis colorectal 
cancer (HNPCC) and the hamartomatous polyposis syndromes: Peutz-Jeghers 
syndrome (PJS), juvenile polyposis syndrome (JPS) and Cowden syndrome (Zbuk 
and Eng, 2007; Lynch et al., 2008; Lynch et al., 2009; Al-Sohaily et al., 2012). 
 
 
 3.1 Familial adenomatous polyposis (FAP) 
FAP was the first recognized colonic polyposis syndrome and is defined as 
a highly penetrant autosomal dominant disease, caused by germline mutations in 
the APC gene. In patients with FAP, germline mutation in one APC allele is present 
in all of their cells, so the initiation of the adenoma-carcinoma sequence, in these 
cases, follows inactivation of the remaining normal copy of APC, often by 
deletion. These mutations, mainly nonsense mutations in exon 15, result, most of 
the times, in a truncated form of the protein, as previously stated (Worthley et al., 
2007; Markowitz and Bertagnolli, 2009; Hughes and Huang, 2011). Clinically, 
patients with FAP present more than a hundred, to thousands of colorectal 
adenomatous polyps usually during the second/third decade of life. These 
patients have a risk of almost 100% of developing CRC during lifetime, unless this 
distinctive natural history is interrupted by surgical intervention (Rustgi, 2007). In 
addition to colorectal neoplasia, the occurrence of several extracolonic tumors is 
increased in FAP; The FAP variant of Gardner syndrome, for instance, is 
characterized by the development of colonic polyposis, desmoid tumors, 
osteomas and benign skin tumors, whilst Turcot syndrome is defined by 
occurrence of colorectal neoplasms and brain cancer. Mutations at the 3’ or 5’ of 
the APC gene, most commonly in exons 4 and 9,  result in an attenuated 
polyposis phenotype – attenuated familial adenomatous polyposis (AFAP) -  which 
is a less aggressive form of the disease characterized by delayed age of onset and 
fewer colorectal polyps (Gryfe, 2009; Hughes and Huang, 2011). 
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3.2 MUTYH-associated polyposis (MAP)  
Reported only in 2002, this is the first hereditary CRC syndrome with an 
autosomal recessive transmission. With an almost complete penetrance and 
variable expression, MAP is caused by bi-allelic mutations in the MUTYH gene, 
which is a base excision repair (BER) gene, targeting oxidative DNA damage 
(Power et al., 2010). However, monoallelic carriers do not carry an increased risk 
of CRC (Balaguer et al., 2007). Inactivation of this gene may result in several other 
mutations, especially in APC gene, which may explain the similar phenotype 
found in FAP (Hughes and Huang, 2011). Clinically, patients with MAP syndrome 
have multiple colorectal adenomatous polyps and have a risk of approximately 
65% of developing CRC during their lifetime. Furthermore, MAP is usually 
diagnosed at an older age than FAP, around the fourth and fifth decade of life (Al-
Sohaily et al., 2012). 
 
3.3 HNPCC/ Lynch syndrome 
HNPCC or Lynch syndrome is the most common form of hereditary 
colorectal cancer, accounting for nearly 2-5% of all colorectal malignancies (Lynch 
et al., 2008; Gryfe, 2009). It is described as an autosomal dominant disease 
caused by germline mutations in DNA mismatch repair (MMR) genes, particularly 
MLH1, MSH2, PMS2 and MSH6, with 90% of the mutations involving either MLH1 
or MSH2 (Centelles, 2012; Legolvan et al., 2012). As a result of these mutations, 
HNPCC tumors are often, also, characterized as MSI. Families with MSH2 
mutations are more prone to the development of extra-colonic cancers than MLH1 
mutation carriers. MSH6 mutation carriers develop CRC at a more advanced age 
and show an attenuated phenotype, which is thought to be due to partial function 
compensation provided by the MSH3 protein (Lynch et al., 2008; Centelles, 2012). 
Patients with this syndrome develop CRC at a younger age than the general 
population (~45 years vs. 65 years) and despite its designation as a CRC 
syndrome, numerous other cancers appear to occur at increased frequency, such 
as endometrial, ovarian, gastric, pancreatic and urethral tumors (Lynch et al., 
2008; Gryfe, 2009). Phenotypically, patients with HNPCC have a predilection for 
right sided CRC tumors and these are more often poorly differentiated and 
present an excess of mucoid and signet-cell features (Lynch et al., 2008). The 
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HNPCC variant Muir-Torre syndrome is characterized by sebaceous adenomas, 
visceral cancers and keratoacanthomas (Gryfe, 2009). 
 
3.4 Peutz-Jeghers syndrome (PJS) 
PJS is a very rare disease that usually appears in the second or third decade 
of life. It has an autosomal dominant mode of inheritance, caused by mutations in 
STK11 (LKB1) gene. STK11 is a tumor suppressor gene that encodes a serine-
threonine kinase that modulates cell polarity and proliferation (Rustgi, 2007; 
Gryfe, 2009). Clinically, patients have few, but moderate-large sized 
hamartomatous polyps appearing mainly in the small bowel and colon and 
confering an increased risk for CRC (Zbuk and Eng, 2007).  In 95% of PJS cases, 
patients present a distinctive mucocutaneous pigmentation most commonly seen 
on the vermillion border of the lips, hands and feet, which may fade after 
puberty. Also, patients with this syndrome have an altered risk for other cancers: 
gastric, pancreatic, breast, ovarian, uterine, cervical and lung (Rustgi, 2007).  
 
3.5 Juvenile polyposis syndrome (JPS) 
It affects one in 100,000 births and its phenotypic manifestations are 
found in childhood to adolescence. Similar to PJS, this autosomal dominant 
condition is characterized by the presence of three to five juvenile polyps in the 
gastrointestinal tract (Rustgi, 2007; Gryfe, 2009; Centelles, 2012). Most polyps 
are benign, but some polyps have the potential for malignant transformation. In 
fact, the lifetime CRC risk in JPS approaches 60% and patients are also at an 
increased risk of developing gastric, small bowel, and pancreatic cancers. 
Germline mutations in BMPRIA, SMAD4 or ENG are reported in JPS, suggesting 
that the TGF-β pathway is critical in the pathogenesis of this disease (Rustgi, 
2007; Gryfe, 2009). 
 
3.6 Cowden syndrome 
With a lifetime risk of CRC of approximately 10%, Cowden syndrome has an 
autosomal dominant mode of transmission affecting one in 200,000 births 
(Rustgi, 2007). It is characterized by the presence of hamartomatous polyps 
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throughout the GI tract associated with cutaneous manifestations, such as acral 
verrucous papules, fibromas of the oral mucosa and trichilemmomas of the face, 
particularly in the eyes, nose and mouth (Centelles, 2012). At the molecular level, 
Cowden syndrome involves germline mutations in PTEN, which is a tumor 
suppressor gene that encodes a protein responsible for negatively regulating the 
PI3K/AKT pathway (Rustgi, 2007; Hughes and Huang, 2011). 
 
4. HOX genes and cancer 
In the later years, the relevance of the homeobox (HOX) genes in cancer has 
begun to be uncovered, and its absence or aberrant expression has been found to 
be related to the tumorigenic process (Cillo et al., 2001; Lappin et al., 2006; Shah 
and Sukumar, 2010). Functional studies of this group of proteins allowed to 
conclude that they are related to crucial processes of the cell development, such 
as cell growth and differentiation, due to their ability of initiating and controlling 
gene expression cascades that drive development (Hombria and Lovegrove, 2003; 
Lappin et al., 2006).  
HOX genes are present in the genomes of all animals, plants and fungi 
mapped so far, indicating that their origin is ancient and precede the divergence 
of these kingdoms. Shortly after the origins of animals, the primordial HOX gene 
suffered a duplication to form a proto-HOX cluster of two genes, which are still 
present in some cnidara (Figure 8). Later, two duplication events, early in 
vertebrate evolution, resulted in the formation of four clusters, which are seen in 
mammals and birds. Throughout evolution, loss of some of the HOX genes in 
each cluster has also occurred, resulting in the fact that not every primordial 
vertebral HOX gene is represented in each of the four clusters (Lappin et al., 
2006). 
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HOX proteins are a family of transcription factors encoded by 39 genes 
clustered in four unlinked complexes (HOXA, HOXB, HOXC and HOXD clusters), 
each with approximately 200 kb. In its structure, there is a 183bp DNA sequence 
– the homeobox- coding for a 61 amino acid domain defined as the 
homeodomain (HD). This HD is usually located at a terminal or sub-terminal 
position of the corresponding homeoprotein, and is responsible for the 
recognition and binding of sequence-specific DNA motifs, as well as the activation 
or repression of downstream effector target genes. Structurally, each HOX gene is 
composed of 2 exons and 1 intron (Figure 9) (Cillo et al., 2001). 
 
Figure 8- Dendogram illustrating the evolution of HOX clusters. The development of HOX 
clusters is thought to be a consequence of the process of duplication and divergence from a 
primordial HOX gene, estimated to have arisen 1,000 million years ago. Also, the presence of 
clustered HOX genes reflects the complexity of body structure of the different organisms, as simpler 
organisms such as sponges, who lack this characteristic [adapted from (Lappin et al., 2006)]. 
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In the genome, clusters A, B, C and D are located on human chromosomes 
7, 17, 12 and 2 respectively, with each cluster containing a minimum of nine and 
a maximum of eleven HOX genes (Krumlauf, 1994). Genes that are in equivalent 
positions of different clusters (paralogs) are more closely related than adjacent 
genes in the same cluster. Graham et al. (1989), showed that, through parsimony 
analysis of homeodomains, mammal HOX complexes can be aligned with the 
Drosophila complex, suggesting a common phylogenetic origin of both these 
complexes (Graham et al., 1989). Furthermore, HOX genes in different clusters 
with highly homologous homeodomains, can be aligned on the chromosome and 
organized as 13 paralogs groups, and their order of expression in the anterior-
posterior axis of the embryo is collinear with their 3’ to 5’ organization on the 
chromosomes (Duboule and Morata, 1994). This is known as spatial colinearity. 
Therefore, genes mainly located at the 3’ end of the complexes (paralog groups 1 
and 2) are expressed at anterior positions within the hindbrain, whereas genes at 
the 5’ positions (paralog groups 9, 10, 11, 12 and 13) are expressed in more 
posterior regions in the main body axis (Figure 10). Furthermore, genes of this 
family also present temporal colinearity stating that the genes located at 3’ end 
of complexes are expressed earlier in the development of the embryo, as 
opposed to those located at 5’ end, and as the embryo develops more 
progressively 5’ genes are expressed. Also, the latter genes present a dominant 
phenotype compared to 3’ genes, meaning that gene alterations at more distal 
genes (5’) may lead to worse consequences than alterations in more proximal 
genes (3’) depicting posterior prevalence as another characteristic of this family 
of genes. Some members of the complex have been lost during evolution, and as 
a consequence, each cluster maintained a different subset of the 13 paralogs that 
apparently are the same for mice and humans (Zeltser et al., 1996; Lappin et al., 
2006). 
Figure 9- Structure of a homeoprotein. The 
three-dimensional structure of the homeodomain 
is composed of three alpha-helices responsible for 
the binding of DNA motifs [adapted from (Samuel 
and Naora, 2005)]. 
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As already stated, HOX genes exert their function through regulation of 
cell proliferation and differentiation, mainly during embryogenesis and 
organogenesis. They are involved mainly in processes such as limb formation, 
organ system development like the central nervous and digestive systems and the 
establishment of the axial pattern of the organism (Abate-Shen, 2002; Samuel 
and Naora, 2005; Shah and Sukumar, 2010). Cancer and normal development 
share many molecular aspects, as both processes involve shifts in the balance 
between proliferation and differentiation. Hence, it is not surprising to find an 
altered expression pattern of many HOX genes in a variety of tumors, including 
lung, prostate, renal, ovarian, breast, colorectal, Wilms’ tumor, osteosarcoma, 
neuroblastoma and leukemia (Celetti et al., 1993; Cillo et al., 2001; Abate-Shen, 
2002; Nunes et al., 2003).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10- Hox genes organization and 
expression in human with their 
phylogenetic counterparts in 
Drosophila. In humans the four HOX gene 
clusters (A-D) are located on different 
chromosomes, (7p15, 17q21.2, 12q13, 
and 2q31) and each cluster consists of 13 
paralog groups with nine to eleven 
members assigned on the basis of 
sequence similarity and relative position 
within the cluster. Furthermore, a high 
degree of homology is evident between 
the human HOX genes and the Hom-C
genes of Drosophila [adapted from
(Lappin et al., 2006)]. 
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Previous studies showed that different HOX genes have their expression 
altered in different types of tumors. For instance, in most primary breast tumors 
HOXA4, B13, C13, D3 and D13 were found to be upregulated, whereas HOXB3 
was downregulated in comparison to normal breast cells (Cantile et al., 2003). In 
another study, in which HOX expression was assessed in patients with acute 
myelogenous leukemia, HOXA5, A4 and A9 appeared to be overexpressed in 
leukemic cells (Drabkin et al., 2002). Furthermore, the CDX2 gene which is a 
homeobox gene which controls differentiation of intestinal epithelium is 
downregulated in CRC, possibly through promoter methylation (Yu et al., 2007). 
The fact that no single gene expression is uniformly altered in all different types 
of cancer, combined with a lack of a specific pattern of expression across tumors 
has led to the conclusion that, not only expression, but also the function of HOX 
genes in tumors, are tissue-specific (Chen and Sukumar, 2003). Three models 
have been proposed in an effort to classify the mechanisms driving alteration of 
HOX genes: the first is temporospatial deregulation, stating that HOX genes’ 
expression pattern in a tumor from a specific tissue differ temporospatially from 
the one in normal tissue – HOX genes are overexpressed in tumor tissue 
compared to normal tissue; the second mechanism is gene dominance, in which 
HOX genes are overexpressed in an unusual way, in that kind of tissue – HOX 
genes are expressed in tumor tissue but not in the normal tissue from which the 
tumor arose; and the third proposed mechanism is epigenetic deregulation, 
suggesting that downregulation/silencing of HOX genes occurs in a tissue where 
they are normally expressed – HOX genes are downregulated in tumor tissue 
compared to normal tissue (Abate-Shen, 2002; Shah and Sukumar, 2010). 
 From what it is known, the upstream and downstream signaling pathways 
involving HOX proteins remain elusive, furthermore, there has been, in general, a 
failure to identify their specific targets, possible due to the simplicity of the target 
sequences (ATTA) which are present in many gene promoter regions (Chen and 
Sukumar, 2003). It is proposed, however, that deregulation of homeobox genes 
might revert target cells into a less differentiated stem-like state, thereby 
promoting survival and proliferation. Together, these alterations may predispose 
normal cells or tissues to the tumorigenic process. Additional studies concerning 
this group of genes may help achieve a better understanding of the mechanisms 
driving carcinogenesis, as well as discover potential new therapy agents targeting 
this family of genes.  
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4.1 HOXB13 and colorectal cancer 
HOXB13 was first identified by Zeltser and colleagues, in 1996 and was the 
last HOX gene to be discovered (Zeltser et al., 1996). Located on chromosome 17, 
it is the most 5’ member of the HOXB cluster. Structurally, HOXB13 has 2 exons 
with 601bp and 254bp, respectively, with a 5’ UTR region of 585bp and a 3’ UTR 
region of 2027bp [ENSG00000159184, (Flicek et al., 2012)]. Although it is 
separated from HOXB9 by approximately 70 kb, its transcription occurs in the 
same orientation as the other HOX genes, suggesting that the gap between the 9 
and 13 group paralogs results from an insertion, or expansion of genomic DNA 
rather than an inversion of the 5’ end of the cluster. However, the fact that the 
other members of the HOXB cluster are dorsally expressed whilst HOXB13 is 
mostly expressed in ventral areas may suggest different regulation mechanisms 
between this gene and the remaining components of the HOXB cluster. Despite 
the physical separation from the cluster, HOXB13 exhibits spatial and temporal 
colinearity within the main body axis; however, it is not expressed in the 
secondary axes such as the limb and genital tubercule. Its expression is 
predominantly seen in the developing urogenital tract, including the prostate the 
distal colon and rectum, and this pattern of expression continues through 
adulthood (Zeltser et al., 1996). Functionally, HOXB13 is necessary for the normal 
development of the prostate and digestive tract, and has also been implicated in 
the process of fetal skin formation and cutaneous regeneration in the adult 
organism in a mouse model (Mack et al., 2003; Jung et al., 2005).  
Similar to what past studies reported about the involvement of HOX genes 
in carcinogenesis, also HOXB13 has been associated with several types of cancer, 
like ovarian, breast, prostate and colorectal cancer (Jung et al., 2005; Cross and 
Burmester, 2008; Jerevall et al., 2010; Ewing et al., 2012; Chen et al., 2013). In 
fact, Sanz-Pamplona et al. (2011), found an interesting feature of this gene 
regarding its expression in colorectal tumor tissue. In a study where the 
expression of 10 HOX genes was determined, they concluded that 9 of them were 
more expressed in tumors from the proximal colon, and that their expression 
decreased along more distal locations in the GI tract. HOXB13, however, showed a 
reversed pattern indicating that it is more expressed in distal tumors in 
comparison with proximal tumors (Sanz-Pamplona et al., 2011). The mechanisms 
underlying its action and the putative targets downstream its pathways are 
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unknown, and although there has been an effort in order to identify the genetic 
and epigenetic alterations of HOXB13 in carcinogenesis, there is not, yet, a 
consensus regarding its implication as a tumor suppressor or oncogene in the 
different cancers. In 2005, in an attempt to answer these questions, Jung and 
coworkers showed that HOXB13 was downregulated in CRC, when they studied 
the expression of this gene in colorectal tumorigenesis and its involvement in the 
β-catenin/TCF signaling pathway. They also demonstrated that HOXB13 
suppresses the expression of MYC, which is overexpressed in CRC, by 
suppressing TCF4 activity in tumorigenic cells (Jung et al., 2005). MYC oncogene 
is a target of the Wnt signaling pathway, repressed by wild-type APC and activated 
by an unusual excess of β-catenin in association with TCF4, usually as a result of 
mutations in APC (He et al., 1998). Therefore, loss of HOXB13 may stimulate the 
expression of MYC leading to the development of CRC (Jung et al., 2005). The 
ability of HOXB13 to suppress TCF4 has been previously reported in prostate 
cancer cell lines as well (Jung et al., 2004), which may render downregulation of 
MYC, through suppression of TCF4, a possible mechanism of action for this 
transcription factor.  
Another example of the activity of HOXB13 as a tumor suppressor gene in 
CRC was demonstrated by Ghoshal et al. (2010), in a study based on the 
epigenetic mechanisms controlling gene expression in human tumors and CRC 
cell lines (Ghoshal et al., 2010). The role of epigenetic mechanisms in CRC is well 
characterized, particularly through the CIMP pathway and promoter methylation 
of MLH1 gene, but a large number of methylation targets remain to be elucidated. 
In this study, the downregulation of HOXB13 was proposed to be a consequence 
of its methylation, at an upstream CpG islang, by DNMT3B. DNMT3B is a DNA 
methyltransferase (DNMT) that plays an important role in “de novo” CpG island 
methylation and it was previously reported to be overexpressed in colon cancer 
and associated with the CIMP phenotype (Nosho et al., 2009). Additionally, in the 
same study, they also found that HOXB13 inhibited the growth of colon cancer in 
mice, suggesting, once more, an important role of this gene in colorectal 
carcinogenesis.   
More recently, the discovery of a mutation, the G84E mutation, in HOXB13 
has further implicated this gene in carcinogenesis (Ewing et al., 2012). The 
mechanisms by which this mutation might act to promote carcinogenesis are 
unknown, but its location might give a clue to this problem. This rare mutation 
(<1%) consists in an amino acid substitution from glycine to glutamic acid, and is 
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located in exon 1 in a conserved domain of HOXB13 that has been shown to 
mediate binding to the members of the MEIS protein family. The binding of these 
proteins to the HOXB13 gene is believed to be an important modulator for the 
interaction of HOX proteins to specific DNA or other proteins. Therefore, it was 
suggested that mutations in these regions might alter HOXB13 activity (Akbari et 
al., 2012; Ewing et al., 2012). Several studies have found a strong positive 
association between the HOXB13 G84E mutation and an increased risk for 
prostate cancer (Akbari et al., 2012; Ewing et al., 2012; Chen et al., 2013; 
Kluzniak et al., 2013) and, more recently, this association was also  found in CRC 
(Akbari et al., 2013). Although it accounted for only a small fraction of CRC cases 
in the study, it was shown that the effect size of this mutation (OR: 2.0-2.8) is 
similar, or greater, compared with the effect of other CRC risk alleles, such as 
APC 11307K and those identified by genome-wide association studies (Tenesa et 
al., 2008).  
Since HOXB13 is, only, normally expressed in the prostate and in distal 
colon and rectum, the mechanisms by which it is involved in carcinogenesis in 
these organs might overlap, at least, in part. 
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II. AIMS OF THE STUDY 
 
The specific aims of this work were:  
 
→ To search for mutations in the entire coding sequence of the 
HOXB13 gene, in CRC. Any mutation found would be evaluated 
for its somatic or germline nature by analyzing the paired normal 
colon tissue. 
 
→ To evaluate and compare the mRNA and protein expression 
levels of HOXB13 in tumor and normal tissue, in a paired series 
of samples from different locations in the colon; 
 
→ To correlate the different expression levels of HOXB13 with 
clinicopathological data in CRC patients; 
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III. MATERIAL AND METHODS 
  
1. Sample collection 
A consecutive series of paired tumor and normal tissue samples (fresh 
frozen) from 64 patients with colorectal adenocarcinoma were retrospectively 
analyzed. These patients were diagnosed and surgically treated at the Portuguese 
Institute of Oncology-Porto and were referred to the Genetics Department 
between March 2004 and May 2008 for MSI analysis. After surgery, all tumor 
tissue specimens and the respective adjacent normal mucosa were frozen at -
80ºC. Samples were divided into two groups (proximal and distal) according to its 
anatomic site: distal colon was defined as the large bowel region up to 30cm 
from the anal verge, whilst proximal colon comprises samples removed from 
large bowel regions above 30cm from the anal verge. A total of 67 tumors (3 
patients presented 2 primary tumors) - 50 from distal colon, 17 from proximal 
colon - and 64 normal mucosas - 49 from distal colon, 15 from proximal colon - 
were used for the study. Tumors with MSI-H and/or negative MMR protein 
expression were excluded from the study.  
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Relevant clinicopathological data were available for all patients (Table 5). 
For tumor staging assessment the AJCC criteria were used. This study was 
approved by the institutional review board (Comissão de Ética) of the Portuguese 
Institute of Oncology-Porto, Portugal. 
 
 
 
 
 Samples 
Number of patients, n 64 
Age (years) median; range 47; 30-84 
Gender, n (%) 
             Male  
             Female 
 
34 (53%)  
30 (47%) 
Tissue type, n 
               Tumor 
               Mucosa 
 
67  
64 
Anatomic site, n, (n tumors, n 
mucosas)  
             Proximal colon (= or >30cm) 
             Distal colon (<30cm) 
 
 
32 (17 tumors, 15 normal mucosas) 
99 (50 tumors, 49 normal mucosas) 
Grade, n (%) 
              I 
              II 
              III 
              IV              
 
7 (10%) 
14 (21%) 
32 (48%) 
14 (21%) 
Presence of mutation, n (%) 
              KRAS exon 2 
              BRAF exon 15 
 
22 (33%) 
3 (4%) 
 
 
 
 
 
 
 
 
Table 5- Clinical and pathological characteristics of CRC patients enrolled in the study. 
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2. Mutational analysis 
 
2.1 DNA extraction and quantification 
The isolation of genomic DNA was performed in 15 of the 67 tumor 
samples, since the remaining 52 samples have, previously, been extracted by our 
group, by salting-out-chloroform (Mullenbach et al., 1989), which combines the 
classic phenol/clorophorm extraction technique with the salting-out technique. 
Tumor samples were homogenized in 400µL of SE buffer (6M NaCl [Merck, 
Germany]; 0.5M EDTA [Sigma-Aldrich, Germany]; pH=8.0). After the addition of 
400µL of 10% SDS [Gibco® Invitrogen, Carlsbad, CA, USA] samples were shaken in 
a vortex and digested with 50µL of proteinase K (20mg/mL) [Gibco® Invitrogen, 
Carlsbad, CA, USA], at 56ºC. After digestion, 1mL of 6M NaCl [Merck, Germany], 
was added to the samples, followed by another incubation at 56ºC for 10 
minutes. Then, 1mL of chloroform was added and after rotation/shaking for 30 
minutes the tubes were centrifuged at 2,000 x g for 10 minutes. Supernatant was 
collected to another tube and one volume of isopropanol [Merck, Germany] was 
added, for precipitation to occur. The obtained DNA was washed twice, with 70% 
(v/v) ethanol [Merck, Germany], and eluted in bidestilled water. DNA quality was 
evaluated using a NanoDrop ND-1000® spectrophotometer [NanoDrop 
Technologies, USA]. 
 
2.2 DNA sequencing 
Somatic mutation screening in HOXB13 (exon 1 and 2) in 67 tumor 
samples of 64 patients with colorectal adenocarcinoma was done according to the 
modified Sanger DNA sequencing method (Figure 11), based on the classical 
Sanger sequencing method (Sanger et al., 1977). For this purpose, 50-100ng of 
genomic DNA were amplified in a solution containing  1x Taq reaction buffer 
[Thermo Fisher Scientific, Rockford, USA] (75mM Tris-HCl, 20mM (NH
4
)2SO
4
), 
2.5mM of MgCl
2
 [Thermo Fisher Scientific, Rockford, USA], 10µM of dNTPs 
[Thermo Fisher Scientific, Rockford, USA], 0.5M of each primer (reverse and 
forward) [frilabo], 1.5U of Taq DNA polymerase [Thermo Fisher Scientific, 
Rockford, USA], in a final reaction volume of 30µL. Primers were designed using 
the Primer-BLAST (Basic Local Alignment Search Tool) and its specificity 
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determined using BLASTn, both these tools from National Center for 
Biotechnology Information (NCBI) database (Lewis et al., 2013). Primer sequences 
are present in Table 6. 
 
Table 6- Primers used in mutational analysis of exon 1 and 2 of the HOXB13 gene. 
Gene 
(exon) 
Primer sequence  
1- Forward 
2- Reverse 
HOXB13 
(1) 
 
1- CGAGCTGGGAGCGATTTA 
2- AGCTCCAAGTCTCCCTCCTC 
HOXB13 
(2) 
1- TTGCACGTGCGCCTGTAGGG 
2- GTCTCCCCAGGACACCCCCA 
 
A touchdown PCR was performed in a Veriti termocycler [Applied 
Biosystems, Foster City, CA, USA] according to the following conditions: an initial 
denaturation step at 94ºC for 10 minutes followed by three cycles each with a 
different annealing temperature: i) 5 cycles of 1 minute at 94ºC, 1 minute at 64ºC 
and 2 minute at 72ºC; ii) 5 cycles of 1 minute at 94ºC, 1 minute at 62ºC and 2 
minutes at 72ºC; iii) 25 cycles of 1 minute at 94ºC, 1 minute at 60ºC and 2 
minutes at 72ºC. The final extension step was performed at 72ºC for 7 minutes. 
Amplified products were, then, analyzed by electrophoresis in a 2% (w/v) agarose 
[Lonza Rockland, ME, USA] gel stained with 5µg/µL ethidium bromide [Sigma-
Aldrich, Germany].  
PCR products were purified using the ExoSAP-IT method for the removal of 
primers and dNTPs in excess. Samples were purified adding 1µL of ExoSAP 
solution (1:2, Exonuclease I [Thermo Fisher Scientific, Rockford, USA] 20U/µL: 
FastAP Thermosensitive Alkaline Phosphatase [Thermo Fisher Scientific, Rockford, 
USA] 1U/µL) to 10µL of PCR product, followed by incubation at 37ºC for 15 
minutes, and enzyme inactivation at 80ºC for 15 minutes, both steps performed 
in the termocycler [Applied Biosystems, Foster City, CA, USA]. 
 The purification was followed by the sequencing reaction in which 1µL of 
V3.1 cycle sequencing Ready Reaction Mix [Applied Biosystems, Foster City, CA, 
USA] (dNTPs, ddNTPs-fluorocromes, MgCl
2
, Tris-HCl buffer), 1.9µL of Big Dye® 
Terminator V3.1 5x sequencing buffer [Applied Biosystems, Foster City, CA, USA], 
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3.5M of forward primers (each in a different solution) described above, and 
bidistilled water were added to 50-100ng of the previously purified DNA, to reach 
a final volume of 10µL. The sequencing reaction was performed in the Veriti 
termocycler [Applied Biosystems, Foster City, CA, USA] and consisted of an initial 
denaturation step at 96ºC for 10 minutes followed by 35 cycles of 96ºC for 10 
seconds, 52ºC for 5 seconds and final extension at 60ºC for 4 minutes. 
Sequencing reaction products were purified prior to sequencing, in order 
to remove excess of dNTPs, labeled ddNTPs and non-incorporated primers using 
Illustra Sephadex® G-50 Fine DNA Grade [GE Healthcare, Life Sciences, Cleveland, 
USA] according to standard procedure. After purification, 12µL of deionized 
formamide [Applied Biosystems, Foster City, CA, USA] were added to the products 
to help stabilize the single stranded DNA (ssDNA). Samples were, then, placed in 
the automatic sequencer 3500 Genetic Analyzer [Applied Biosystems, Foster City, 
CA, USA] where they were subjected to capillary electrophoresis. The 
electropherograms for each sample were analyzed with the Sequencing Analysis 
Software v5.4 [Applied Biosystems, Foster City, CA, USA] and the Mutation 
Surveyor® DNA Variant Analysis Software [Softgenetics, State College, PA, USA]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11- Schematic of the process of 
modified Sanger sequencing method. In 
this method, ddNTP's with fluorescent 
markers are used instead of radioactive 
labels, allowing the reaction to be 
performed in a single tube containing all 
four ddNTPs (ddATP, ddTTP, ddGTP, 
ddCTP) each labeled with a different color 
dye. After incorporation in the DNA, the 
resulting labeled fragments are separated 
by capillary electrophoresis to determine 
the identity of each band according to the 
wavelengths at which it fluoresces, and its 
output read in an automatic sequence 
machine [adapted from (Russell, 2005)]. 
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3. Quantitative expression analysis  
 
3.1 RNA extraction and quantification 
Due to the lack of biologic material, total RNA extraction was performed 
only in 53 (2 cases presented 2 tumor samples) of the 67 tumors and in 51 of the 
64 paired normal mucosas using TRIzol® Reagent [Invitrogen Carlsbad, CA, USA] 
according to the manufacturer’s instructions and standard protocol 
(Chomczynski, 1993). Briefly, 1mL of PBS was added to tissue samples for 
homogenization, and after centrifugation at 6,800 x g for 5 minutes, the tissue 
was disrupted into smaller pieces. Samples were, then, collected to tubes with 
matrix lysing [MP Biomedicals, Irvine, CA, USA] (containing 1.4-mm ceramic 
spheres) and after the addition of 1mL of TRIzol® Reagent to each tube, samples 
were homogenized in the Savant FastPrep® FP 120 Cell Disrupter [MP 
Biomedicals, Irvine, CA, USA] at a speed of 6.5m/s for 45 seconds. The 
homogenized samples were transferred to 1.5mL RNAse-free tubes and 200µL of 
chloroform were added to the tubes, which were shaken in a vortex for 15 
seconds and incubated at room temperature for 3 minutes, followed by a 
centrifugation at 12,000 x g for 15 minutes at 4ºC. After centrifugation three 
phases could be clearly distinguished in each tube: a lower red phenol chloroform 
phase containing the protein fraction; an intermediate phase containing the DNA; 
and an upper colorless phase, enriched with RNA. The latter was collected into a 
fresh RNAse-free tube and precipitated by adding 500µL of isopropanol [Merck, 
Germany], incubating at room temperature for 10 minutes after mixing by 
invertion. To collect the RNA, samples were then centrifuged at 12,000 x g for 10 
minutes and the supernatant was discarded. The RNA pellet was washed, twice, 
with 1mL of 75% (v/v) ethanol [Merck, Germany], followed by a centrifugation at 
7,500 x g for 5 minutes. The supernatant was carefully discarded and the RNA 
pellets were dried for 30 minutes at room temperature. RNA pellets were, then, 
eluted in 80-150µL of Nuclease-free water [Qiagen, Hilden, Germany] according to 
pellet size, and placed in ice for 30 minutes. Evaluation of RNA concentration and 
quality was assessed using a NanoDrop ND-1000® spectrophotometer [NanoDrop 
Technologies, USA]. RNA was stored at -80ºC until further use. The DNA and 
protein fractions were also stored at -80ºC for subsequent separation. 
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3.2 cDNA synthesis and amplification 
For gene expression analysis, cDNA was synthesized using Transplex™ 
Whole Transcriptome Amplification (WTA) kit [Rubicon Genomics Ann Arbor, MI, 
USA], according to the manufacturer’s protocol. Briefly, 300ng of template RNA 
were mixed with 2.5µL of WTA Library Synthesis buffer and 2.5µL of WTA Library 
Stabilization Solution, for a total volume of 24µL in nuclease-free water. All 
components were gently mixed and incubated at 70ºC for 5 minutes to denature 
samples, using the Gene Amp PCR System 9700 termocycler [Applied Biosystems, 
Foster City, CA, USA]. After undergoing a cool reaction on ice for 2 minutes and 
the addition of 1µL of WTA Library Synthesis enzyme, the samples were mixed by 
pipeting. These were, then, placed back in the termocycler and incubated at 24ºC 
for 15 minutes, followed by 42ºC for 120 minutes, and finally 95ºC for 5 minutes. 
All samples were immediately chilled on ice or stored at -20ºC until further use. 
After synthesis, 5µL of cDNA were amplified by PCR performed in a 
solution, the WTA Amplification Mix, containing 7.5µL of WTA Amplification 
Master Mix, 1.5µL of dNTP Mix, 5U of TITANIUM Taq DNA polymerase and 60µL of 
nuclease-free water making up a volume of 75µL. Samples were incubated at 95ºC 
for 3 minutes, followed by 17 cycles of 94ºC for 20 seconds and 65ºC for 5 
minutes in the same termocycler previously used. 
 
3.3 cDNA purification  
After amplification, cDNA samples were purified using the QIAquick® PCR 
Purification Kit [Thermo Fisher Scientific, Rockford, USA] according to 
manufacturer’s protocol, in order to remove nucleotides, enzymes and other 
impurities associated with the amplification PCR. Briefly, 5 volumes of Buffer PB 
were added to 1 volume of the PCR reaction and this solution transferred to a 
QIAquick column placed in a 2mL collection tube. After centrifugation at 17,900 x 
g for 60 seconds, the flow-through was discarded, and the column placed in the 
same tube. The samples were then washed with 750µL of Buffer PE, followed by 
two centrifugations at 17,900 x g for 60 seconds, to remove residual wash buffer. 
The flow-through was discarded and the columns were placed in clean 1.5mL 
tubes ready for elution. Fifty microliters of water were added to each column, 
followed by centrifugation at 17,900 x g for 60 seconds. To reach a final volume 
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of 100µL and maximum yield, these last two steps were performed twice. The 
purified cDNA samples were stored at -80ºC until further use. 
 
3.4 Quantitative reverse-transcriptase PCR (qRT-PCR) 
HOXB13 transcripts were quantified by real time quantitative PCR. The 
reactions were performed using predeveloped Taqman gene expression assays 
from Applied Biosystems (Figure 12). For HOXB13, the Hs00197189_m1 assay, 
spaning the exon-exon junction was used, and the endogenous control ACTB 
4333762F assay was used to normalize cDNA input. Both expression assays were 
performed simultaneously, in 96-well plates in a 7500 Real Time PCR System 
[Applied Biosystems, Foster City, CA, USA] according to the recommended 
protocol. In brief, in each well, 2µL of previously synthesized cDNA, 1µL of 
TaqMan® Gene Expression Assay, 10µL of SensiFAST Probe Lo-ROX mix (2x) 
[Bioline, London, UK] and 7µL of bidistilled water were mixed. PCR conditions 
were those predefined by the manufacturer: 50ºC for 2 minutes, 95ºC for 10 
minutes, 45 cycles at 95ºC for 15 seconds and 60ºC for 1 minute. All cDNA 
samples were run in duplicates.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12- TaqMan hydrolysis probe 
principles. The 5'-nuclease activity of 
thermostable polymerases used in the 
PCR has the ability to cleave
hydrolysis probes during the 
amplicon extension step, separating 
the reporter fluorophore (R) from a 
quencher (Q). This separation causes 
the reporter to emit fluorescence 
when excited by an external light 
source (hv), which is proportional to 
the amount of product formed, at 
each PCR cycle [adapted from (Koch, 
2004)]. 
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gDNA extracted from the LNCaP cell line was used to prepare four 
consecutive DNA dilutions (dilution factor of 10x) that were used as standards in 
each plate, allowing the construction of a standard curve to assess PCR efficiency. 
Two negative controls were used for each gene, in each plate.  
The results were analyzed using the 7500 Software v2.0.6 [Applied 
Biosystems, Foster City, CA, USA]. A run was considered valid when the slope of 
the corresponding standard curve was between -3.38 and -3.32, corresponding to 
a PCR efficiency >99%. 
For each sample, the mean quantity of HOXB13 expression levels was 
normalized against the mean quantity of ACTB expression levels, using the 
comparative C
T
 method (Schmittgen and Livak, 2008). 
 
3.5 Protein extraction and quantification 
Protein extraction was performed in 6 tumor samples (3 from distal colon, 
3 from proximal colon) and 5 normal mucosas (2 from distal colon, 3 from 
proximal colon), selected based on qRT-PCR data and anatomic site. The 
extraction was performed on the protein and DNA fractions stored at -80ºC 
during RNA extraction by TRIzol® Reagent [Invitrogen Carlsbad, CA, USA]. For an 
improvement of protein yield we applied slight modifications to the standard 
TRIzol procedure, according to Likhite et al. (2011) (Likhite and Warawdekar, 
2011). Samples were thawed on ice and 1mL of isopropanol was added to 
precipitate the proteins which occurred after inversion and incubation at room 
temperature, for 10 minutes. The samples were, then, centrifuged at 12,000 x g 
for 10 minutes at room temperature, to allow the formation of the protein pellet, 
and the supernatant discarded. The pellets were washed in 1mL of a solution 
containing 0.3M of guanidine hydrochloride (GuHCl) [Sigma-Aldrich, Germany] in 
95% (v/v) ethanol and incubated at room temperature for 20 minutes, followed by 
a centrifugation at 7,500 x g for 5 minutes at 4ºC. These steps were performed 
twice, followed by an overnight incubation with 1mL of the same solution, at 4ºC. 
The next day, samples were centrifuged at 7,500 x g for 5 minutes at 4ºC and the 
supernatant discarded. Two milliliters of 100% (v/v) ethanol were added, the 
samples put in a vortex for 10 seconds and incubated at room temperature for 20 
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minutes. After a brief centrifugation at 7,500 x g for 5 minutes at 4ºC, the 
ethanol was discarded and the pellets were air-dried for 5-10 minutes. To dissolve 
the pellet, 200µL of a solution containing 1% SDS and 8M urea buffer (1:1) were 
added to each tube and these, incubated at 50ºC until dissolution of the pellet. 
The tubes were, then, centrifuged at 10,000 x g for 10 minutes at 4ºC to pellet 
insoluble material and the supernatant collected to a fresh tube.  
The quantification of the extracted protein was performed using the 
Pierce® BCA Protein Assay Kit [Thermo Fisher Scientific, Rockford, USA] according 
to the manufacturer´s instructions. This method relies on the chelation of copper 
with protein in an alkaline environment, which then reacts with bicinchoninic acid 
(BCA) giving rise to a purple-colored reaction product. By determining the amount 
of this water-soluble reagent, by measuring the absorbance of the solution at 
562nm, protein quantification can be easily estimated. A series of five dilutions 
(dilution factor 2x) of bovine serum albumin (BSA) were prepared (2,000µg/mL; 
1,000µg/mL; 500µg/mL; 250µg/mL; 125µg/mL) to be used as standards in the 
assay alongside the samples, allowing the construction of a standard curve for 
relative protein quantification. Twenty five microliters of the previously extracted 
protein, or standard sample, were mixed with 200µL of BCA Working Reagent 
(50:1 Reagent A:B). One negative control was prepared simultaneously. After 
incubation at 37ºC for 30 minutes, samples were transferred to a 96-well 
microplate and its absorbance measured at, or near, 562nm, in the multi-mode 
microplate reader FLUOstar Omega [BMG Labtech, Ortenberg, Germany]. The 
results were then analyzed using the MARS Data Analysis software [BMG Labtech, 
Ortenberg, Germany]. Proteins were stored at -20ºC until further use.  
 
3.6 SDS-PAGE and Western Blot 
Protein expression levels of HOXB13 were evaluated by Western Blot using 
a specific anti-HOXB13 antibody (ab28575) [Abcam, Cambridge, UK] as depicted 
in Figure 13. Briefly, 10µg of protein from each sample were mixed with 5x 
loading buffer (0.5M Tris-HCl pH=6.8, 2% SDS, 10% glycerol, 0.05% bromophenol 
blue and 5% β-mercaptoethanol) (5:1) and denaturated at 95ºC for 5 minutes. The 
electrophoretic separation of proteins was done in a 10% polyacrylamide gel 
under denaturating conditions. Briefly, a running gel containing 10% (w/v) 
acrylamide/bis-acrylamide solution, 0.375M Tris-HCl pH=8.8, 0.1% (w/v) SDS, 4% 
(v/v) glycerol, 0.1% (w/v) APS and 0.1% (v/v) TEMED; and a stacking gel containing 
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4% (w/v) acrylamide/bis-acrylamide, 0.126M Tris-HCl pH=6.8, 0.1% (w/v) SDS, 
0.1% (w/v) APS and 0.2% (v/v) TEMED were prepared. The proteins were applied in 
the stacking gel and separated in the Mini-PROTEAN® Electrophoresis System [Bio-
Rad, Hercules, CA, USA] in Tris/Glycine SDS running buffer [0.025M Tris, 0.192M 
glycine and 0.1% SDS pH=8.3] at 120V/cm for 1 hour and 45 minutes.    
Proteins were, then, transferred to a 0.1µm nitrocellulose membrane 
[Whatman, Dassel, Germany] to make the proteins accessible for antibody 
detection, and the sandwich system mounted on the transfer unit of the Mini-
PROTEAN® Electrophoresis System [Bio-Rad, Hercules, CA, USA] according to the 
manufacturer´s instructions. The transfer occurred at 50V/cm for 1 hour at 4ºC 
in Tris/Glycine transfer buffer [0.025M Tris, 0.192M glycine, 4% (v/v) methanol]. 
After electroblotting, membranes were incubated in blocking solution [5% (w/v) 
nonfat dry milk in TBST (0.01M Tris-buffered containing 0.1% (v/v) Tween-TBS)] 
for 1 hour at room temperature with gentle shaking to reduce non-specific 
binding. Then, the blocking solution was replaced with the primary antibody 
solution containing the rabbit polyclonal antibody for HOXB13 [Abcam, 
Cambridge, UK], diluted in the blocking solution (1:250), and the membranes 
incubated overnight at 4ºC with shaking. After three washing steps with TBST for 
a minimum of 5 minutes, the membranes were incubated with a horseradish 
peroxidase-conjugated secondary anti-rabbit antibody [Santa Cruz Biotechnology 
Inc., Santa Cruz, CA, USA] diluted 1:100,000 in blocking solution for 1 hour at 
room temperature. Afterwards, membranes were subjected to chemiluminescence 
detection using Immun-Star WesternC Chemiluminescent Kit (Bio-Rad, Hercules, 
CA, USA) and exposed to Amersham Hyperfilm (GE Healthcare, Life Sciences, 
Cleveland, USA). To ascertain equal loading of protein, membranes were striped 
in a solution [2% (w/v) SDS, 0.0625M Tris-HCl pH=6.8, 0.114M β-
mercaptoethanol] and reprobed with a monoclonal mouse antibody against β-
actin [Sigma-Aldrich, Germany], diluted 1:8000 in blocking solution. The specific 
protein bands were then visualized by autoradiography. 
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3.7 Immunohistochemistry 
Ten colorectal FFPFE tissues, each containing tumor and normal adjacent 
tissue (of 67 samples) were sectioned at a thickness of 4 µm. Slides were 
deparaffinized in two passages through xylene and hydrated by a decreasing 
gradient of alcohols until 50% alcohol according to standard protocol (Figure 14). 
Epitope retrieval was performed with pre-heated sodium citrate for 20 minutes 
and all staining procedure was accomplished using NOVOLINK™ Max Polymer 
Detection System [Novocastra] according to the manufacture’s protocol. The 
antibody for HOXB13 protein, mouse monoclonal anti-human IgG
1 
(sc-28333) 
Figure 13- Western Blot technique workflow. The technique is used to detect a specific protein 
and depends on its reaction with an antibody. After separation of proteins by electrophoresis, these 
are transferred from a polyacrylamide gel to a membrane where they are incubated with a specific 
antibody. Protein detection is performed by autoradiography (adapted from 
http://www.virology.ws/). 
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[Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA] was diluted to 1:50 and 
incubated at room temperature for 2 hours. Antigen-antibody reaction was 
visualized after a 5 minute incubation with diaminobenzidene (DAB) from the 
NOVOLINK™ Max polymer detection System [Novocastra]. Slide counterstaining 
was achieved with hematoxylin for 20 seconds at room temperature and the final 
step of the protocol was dehydration. The coverslipped slides were examined in a 
microscope. 
 
 
 
 
 
 
Figure 14- Immunohistochemistry technique workflow 
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IV. RESULTS 
 
1. HOXB13 mutational analysis 
A total number of 67 (30 women, 34 men) tumor DNA samples from 
proximal (17/67) and distal colon (50/67) were analyzed by DNA sequencing in 
search for mutations in exon 1 and 2 of the HOXB13 gene. No deleterious 
mutations were identified after analysis of the respective electropherograms, but 
some known polymorphisms were identified in exon 1 of HOXB13 and are 
depicted in Table 7.  
 
dbSNP ID Exon DNA Variant type Protein 
# Individuals 
[N(%)] 
rs9900627 1 c.513T>C Synonymous p.(=) 9  (13) 
rs8556 1 c.366C>T Synonymous p.(=) 11 (16) 
 
 Since no mutations were found in the CRC tumors, no further sequencing 
was performed in the paired normal colon samples, as eventual germline 
mutations would most likely also be detectable in the tumors.   
Table 7- Exon variants identified after sequencing the entire HOXB13 coding sequence. 
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2. HOXB13 mRNA expression 
In order to assess global HOXB13 expression in our samples, we measured 
its relative expression levels, by qRT-PCR, in 51 colorectal tumors (2 cases 
presented 2 tumor samples) - 40 from distal colon, 11 from proximal colon - and 
45 normal mucosas - 36 from distal colon and 9 from proximal colon. Due to 
technical issues, we could not measure HOXB13 expression levels in 2 tumors 
and 6 normal mucosa samples of the previously extracted RNA samples.  
Significant differences were observed between these two types of tissues, 
with lower expression of HOXB13 transcript levels in tumors when compared with 
normal mucosas (Mann-Whitney U test, p<0.01) (Figure 15). 
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Since it has been described that HOXB13 is normally expressed in 
differentiated tissues only in distal colon (in addition to prostate) (Zeltser et al., 
1996), we then compared the HOXB13 mRNA expression between proximal and 
distal normal colon samples  (Figure 16). As expected, we found a statistically 
significant difference between the HOXB13 expression in normal mucosa in 
proximal and distal colon (Mann-Whitney U test, p<0.001), the latter presenting a 
higher expression of this gene.  
 
Figure 15- Distribution of HOXB13 mRNA expression levels in colorectal tissues [normal 
mucosa (n=45) and tumor (n=51)]. The represented scale is logarithmic. 
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We, then, compared the HOXB13 mRNA expression levels between tumors 
from proximal and distal colon, and no statistically significant difference was 
found, however there is a clear trend suggesting higher levels of HOXB13 
expression in tumors from distal colon (Figure 17) (Mann-Whitney U test, p=0.07). 
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Figure 16- Distribution of HOXB13 transcript expression levels in colorectal normal mucosa 
from proximal (n=9) and distal colon (n=36). The represented scale is logarithmic. 
Figure 17- Distribution of HOXB13 transcript expression levels in colorectal tumors from 
proximal (n=11) and distal colon (n=40). The represented scale is logarithmic. 
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Given the findings described above in terms of global expression of 
HOXB13 in normal mucosa versus tumor tissue (Figure 15), and between 
proximal and distal normal (Figure 16) and tumor colon (Figure 17), we sought to 
compare the expression of HOXB13 between normal and tumor tissue in paired 
samples. For that purpose, the ratio between the relative HOXB13 expression 
levels in tumor tissue and the corresponding normal mucosa was calculated 
(HOXB13expression
Tumor
/HOXB13expression
Mucosa
) for each of the 45 pairs (Figure 
18). Interestingly, most samples from proximal colon exhibited a positive ratio, 
implying that the expression levels of HOXB13 in those tumors were higher than 
in the paired normal mucosa. Conversely, most distal tumors presented a 
HOXB13 mRNA expression below that of the paired normal mucosa. Furthermore, 
the proportion of cases with higher HOXB13 expression in tumors than in normal 
mucosa (Ratio+) is higher in proximal colon than in distal colon. Distal colon, 
however, exhibits higher proportion of cases with higher HOXB13 expression in 
normal mucosas than in tumors (Ratio-) (Fisher´s exact test, p<0.0001) (Figure 
19).  
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This difference can also be easily visualized by plotting all HOXB13 
expression ratios between tumor and normal mucosa for both anatomic sites, as 
seen in Figure 20, where a statistically significant difference is seen (Mann-
Whitney U test, p<0.01). 
Figure 19- Graphic depicting the proportion of cases with positive and negative HOXB13 
expression ratios in proximal and distal colon.  
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Although the difference was not statistically significant between tumors 
and normal tissue of the proximal colon, presumably because there were only 9 
paired samples, one can easily see, in Figure 21 an inversion of patterns in terms 
of HOXB13 expression when comparing proximal with distal colon samples. In 
the distal colon, the lower HOXB13 expression in tumor samples compared to the 
paired normal mucosa was statistically significant (Wilcoxon Signed-rank test, 
p<0.001). 
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Figure 21- Distribution of HOXB13 transcript expression levels in paired samples from 
proximal [normal mucosa (n=9) and tumor (n=9)] and distal colon [normal mucosa (n=36) 
and tumor (n=36)]. The represented scale is logarithmic. ns- not significant 
Figure 20- Boxplot depicting the differences in the ratios of HOXB13 expression between 
tumor and normal tissue in each paired sample, in proximal (n=9) and distal colon (n=36). The 
represented scale is logarithmic. 
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Hence, tumors located on the distal colon tend to have a lower expression 
of HOXB13 in comparison to the expression in the adjacent tissue, while the 
opposite trend was depicted for tumors and normal mucosas from the proximal 
colon. 
Finally, we compared the relative HOXB13 expression levels between 
tumors with presence and absence of the previously found SNPs (Figure 22). 
However, we found no statistically significant differences between these two 
groups (Mann-Whitney U test, p>0.05).  
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Figure 22- Distribution of HOXB13 transcript expression levels in colorectal tumors, in 
presence or absence of SNPs in exon 1. The represented scale is logarithmic. ns- not 
significant. 
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3. HOXB13 protein expression  
Western Blot 
Protein extracted from tissue samples was analyzed by Western Blot for 
HOXB13. We were able to assess protein expression in 6 samples (3 pairs) from 
the proximal colon and in 5 samples (1 pair and another case with 2 primary 
tumor samples and the respective normal mucosa) from distal colon. Differences 
in HOXB13 protein level expression between colorectal tumor and normal mucosa 
are illustrated in Figure 23. A single band was observed in both blots with 
approximately 32kDa. 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Although a clear pattern of expression could not be seen across samples in 
each location, possibly because of the reduced number of pairs, we saw that in 
proximal colon, 2 of 3 cases displayed higher levels of protein in tumor compared 
Figure 23- Protein gel blot analysis for HOXB13 in colorectal tumors and normal mucosas 
from proximal (A) and distal colon (B) and the respective ratio values of HOXB13 expression 
levels for each case. The housekeeping gene actin was used as a loading control. 
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with the respective normal mucosa, whereas the other case showed higher levels 
of protein in the normal mucosa comparing with tumor tissue. In the distal colon, 
two cases exhibited higher levels of protein in normal mucosa comparing with 
tumor tissue, whereas in the other case normal mucosa and tumor seem to 
exhibit the same levels of protein expression.  
When looking at the corresponding ratio values of HOXB13 expression for 
each case, we found protein expression results to be consistent with the most 
extreme ratio values (positive or negative) of mRNA expression seen in two 
samples (9270 and 9232), as positive ratios would implicate higher levels of 
protein expression in tumors, and negative ratios higher levels of protein 
expression in normal mucosas. For the remaining cases no consistency between 
protein and mRNA levels was seen. 
   
 
Immunohistochemistry 
A total of 10 samples (7 from distal and 3 from proximal colon) were 
submitted to IHC for detection of HOXB13 protein expression. Three patterns of 
protein expression could be seen across samples: i) more HOXB13 protein 
expression in normal tissue (Figure 24A), ii) same apparent expression in tumor 
and normal tissue (Figure 24B) and iii) more expression in tumor tissue (Figure 
24C). Of the 10 samples, only 6 could be compared with the ratios of HOXB13 
mRNA expression. Due to technical issues regarding the qRT-PCR, we could not 
compare protein expression with the respective ratio values of mRNA in the 
remaining 4 samples. Two of the 6 samples presented the first pattern of protein 
expression, 2 presented the second pattern and the remaining 2 samples were 
associated with the third pattern. 
 The sample representing the first pattern of protein expression (Figure 
24A) showed a FoldChange (FC) value of HOXB13 expression of -9.9, indicating 
that in this case, the normal mucosa presented approximately more 9.9 times 
expression of this gene compared to tumor tissue. The sample with the second 
pattern of protein expression (Figure 24B) had a FC value of 1.4, which means 
that in this case, the tumor expresses nearly 1.4 times more HOXB13 than the 
adjacent normal tissue, corresponding to a protein pattern where no objective 
differences are seen between the two types of tissues. The remaining sample 
(Figure 24C) presented a FC of 153.7, meaning that the tumor expressed 153.7 
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times more HOXB13 than the normal mucosa, therefore being compatible with 
the results of immunohistochemistry.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For the 6 samples for which had the available qRT-PCR data, we saw 
consistency between the protein expression given by immunohistochemistry and 
the mRNA levels for FC values greater than 2 [associated with iii)] and smaller 
than -2 [associated with i)]. For FC values between 2 and -2, the 
immunohistochemistry results could not detect differences in HOXB13 protein 
expression between normal and tumor tissue [associated with ii)]. 
 
 
 
 
 
 
Figure 24- Immunohistochemistry for detection of HOXB13 protein. Representation of the 
three patterns of HOXB13 protein expression obtained in the 10 samples tested. A- More 
expression in normal tissue (FC=-9.9); B- Same expression in tumor and normal tissue 
(FC=1.4); C- More expression in tumor tissue (FC=153.7). 
A B 
C 
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4. Clinicopathological associations 
No statistically significant differences were observed for HOXB13 
expression and age (Mann-Whitney U test, p>0.05), gender (Mann-Whitney U test, 
p>0.05), tumor grade (Kruskal-Wallis test, p>0.05), or KRAS (Mann-Whitney U test, 
p>0.05) and BRAF mutations (Mann-Whitney U test, p>0.05). The respective p 
values between HOXB13 expression and each clinicopathological variable are 
depicted in Table 8. 
 
 
 p value 
Age 0.567 
Gender  0.340 
Grade 0.638 
Mutation status  
           KRAS exon 2 
           BRAF exon 15 
 
0.376 
0.565 
 
 
 
 
 
Table 8- Associations between the HOXB13 expression and clinicopathological data from the 
patients enrolled in the study. 
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V. DISCUSSION 
 
Currently, CRC is the fourth leading cause of cancer mortality in the world 
(Jemal et al., 2011) and, due to its asymptomatic nature early in tumor 
development, nearly 25% of patients present metastasis at the time of diagnosis 
(Van Cutsem et al., 2010) which hinders an effective treatment and reduces the 
chance of remission of the disease. The understanding of the molecular features 
underlying this condition has become a central issue in cancer research in recent 
years, gaining weight as a valuable and ancillary tool for, both, CRC diagnosis and 
treatment. Following the classical adenoma-carcinoma postulate (Vogelstein, 
1990), the subsequent definition of, at least, three molecular pathways of CRC - 
CIN, MSI and CIMP - gave clinicians and researchers a different, and clearer, 
perspective of the biological characteristics of the distinct subtypes of CRC, thus 
unveiling the complexity of this disease (Ogino and Goel, 2008). Notwithstanding, 
the boundaries of the cellular and molecular characteristics of CRC are not yet 
completely defined, as new genes and pathways are continuously being 
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associated with this disease. The study of HOX genes in CRC has proven to be an 
interesting approach to this subject.  
 Firstly, we sought to find mutations in exon 1 and 2 of the HOXB13 gene 
by the modified Sanger sequencing method, in a series of 67 colorectal 
adenocarcinomas. Although we did not find any significant alteration, besides the 
already identified SNPs (Ewing et al., 2012) in the samples analyzed, we 
emphasize the fact that, unlike the studies involving mutation screening in 
HOXB13 so far, which aimed specifically for the search of germline mutations 
(Bessede and Patard, 2012; Ewing et al., 2012; Walsh, 2012; Akbari et al., 2013), 
we used, for the first time, tumor tissue in order to assess the presence of 
mutations. This provides the advantage of detecting both somatic and germline 
mutations in the same sample of tissue, rendering this approach more cost-
effective than the ones used so far. Furthermore, the only mutations found in 
HOXB13 (Y88D, L144P, G216C, R229G and G84E in patients with prostate cancer) 
exhibit a very low frequency (Ewing et al., 2012). Particularly, the G84E mutation 
has been also associated with CRC (and to date, the only mutation of HOXB13 
associated with this disease) with a frequency of approximately 0.48% (Akbari et 
al., 2013). The low frequency of the alterations already identified in HOXB13 may 
help explain the lack of alterations found in our study, which may, therefore, 
pinpoint the reduced number of samples as a limitation of the study when 
searching for mutations in this gene.      
 Concerning the expression of HOXB13 in CRC, we ascertained its relative 
expression in tumor and normal tissue samples, taking into account their 
localization in the colon. Our overall results indicated that the HOXB13 gene was 
downregulated in tumor tissue when compared with normal mucosa, which would 
be compatible with a role as a tumor suppressor gene in accordance to what has 
been previously found by Jung et al. (2005). In this study, HOXB13 expression 
was evaluated in tumors from distal colon and rectum, as well as in the respective 
normal tissue and it was found to be diminished in 62% of the tumors analyzed 
when compared to normal tissue (Jung et al., 2005). In fact, a mechanism of 
action for the HOXB13 gene in CRC was proposed, with a link to the Wnt pathway, 
and indeed defining its role as a tumor suppressor gene. Thus, when HOXB13 is 
downregulated, there is an upregulation of TCF4, which in turn binds to β-catenin 
and leads to the transcriptional activation of MYC (Jung et al., 2005). Additionally, 
one of the most commonly mutated genes in CRC – the APC gene – is also 
associated with the Wnt pathway (Worthley et al., 2007; Markowitz and 
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Bertagnolli, 2009). In the presence of mutated APC there is an accumulation of β-
catenin and inappropriate activation of this signaling pathway, as well. Hence, the 
effects of HOXB13 downregulation in CRC cells may provide an alternative 
mechanism for Wnt pathway activation in the presence of wild-type APC. 
Furthermore, since mutated APC is considered a hallmark of the CIN pathway in 
CRC, and given the similarities (independent of the magnitude of β-catenin 
activation) of this proposed mechanism for HOXB13, these data combined may 
suggest an implication of HOXB13 gene in the CIN pathway of colorectal 
carcinogenesis. 
The presumed differences between the HOXB13 expression in normal 
mucosas from proximal and distal colon were, then, evaluated. As expected, a 
significant higher expression of HOXB13 in mucosas from distal colon was found, 
in comparison to mucosas from proximal colon. However, mucosas from 
proximal colon also expressed (lower) levels of HOXB13 expression, something 
that was unexpected because, normally, HOXB13 is described as being expressed 
only in prostate and distal colon (Zeltser et al., 1996; Sreenath et al., 1999). 
However, the normal mucosas that were analyzed were from cancer patients and 
not normal individuals. In fact, morphologically normal mucosa from each case 
was resected as far as possible, but necessarily relatively close to the tumor in 
colectomy specimens. Since it is known that through the field effect some early 
molecular events in carcinogenesis, such as epigenetic deregulation, might be 
present in normal morphological tissues adjacent to the actual neoplastic cells 
(Leung et al., 2001; Chai and Brown, 2009; Hawthorn et al., 2013), this physical 
proximity between tumor and normal tissue may justify why some of tumor 
features, such as altered expression of specific genes, can also be found in the 
normal adjacent tissue. This may explain why HOXB13 was also expressed in 
normal tissue from proximal colon. To the best of our knowledge, this is the first 
study to analyze HOXB13 expression in normal mucosa from proximal colon in 
CRC patients. 
Concurrently, the same comparison was performed for tumors according 
to their location in the colon. Whereas the expression of most HOX genes in 
colorectal tumors appear to be expressed in a gradient, being more expressed in 
the proximal colon and decreasing along more distal locations, HOXB13 shows a 
reversed pattern of expression (Sanz-Pamplona et al., 2011). In our study, we 
found a tendency for higher HOXB13 expression levels in distal tumors, but the 
difference did not reach statistical significance (p=0.07). In fact, a potential 
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concern of studies that fail to detect distinct expression patterns between normal 
and tumor tissue is the possibility of insufficient statistical power to detect 
biologically meaningful differences, due to a small sample size. Since we only 
analyzed 11 tumors from proximal colon, this may be a possible explanation for 
the lack of statistical significance obtained in this comparison. Nonetheless, this 
tendency that the pattern of genetic changes involved in proximal and distal 
colon are different, as previously described by our group for genes such as KRAS 
(which is more commonly mutated in distal colon), BRAF, BAX, IGF2R, MSH3, 
MSH6 and TGFBR2 (which are common in proximal colon) (Pinheiro et al., 2010).  
Given the differences between proximal and distal locations regarding the 
HOXB13 expression of both tumor and normal mucosas, we calculated the ratios 
between HOXB13 expression in tumors and normal mucosas for each case 
(HOXB13expression
Tumor
/HOXB13expression
Mucosa
) and compared these ratios in both 
locations. Overall, higher ratios in proximal colon than in distal colon were found, 
indicating that proximal colon tumors expressed more HOXB13 with respect to 
the adjacent tissue. Concurrently, we also found that, in distal colon, HOXB13 
expression is diminished in tumors in comparison with the respective normal 
mucosa. As previously stated, information about the mechanisms regulating the 
expression of HOXB13 is scarce. Nonetheless, a model has been suggested, 
identifying promoter methylation of HOXB13 by DNMT3B as the event responsible 
for its downregulation in CRC. In this study, the methylation status of a group of 
specific genes, including HOXB13, was assessed in colon cell lines and in colon 
tumors, as well as in the respective normal mucosa (Ghoshal et al., 2010). 
HOXB13 downregulation by epigenetic regulation might suggest a possible 
implication of HOXB13 in the CIMP pathway of CRC. The presence of epigenetic 
events in CRC has been assessed in past studies, whether by DNA aberrant 
methylation (Simmer et al., 2012) or microRNA regulation (Hogan et al., 2012), 
both implicated in tumor formation and progression. The fact that most CIMP 
positive tumors are also MSI-H and exhibit a BRAF mutation (Ogino and Goel, 
2008), however, indicates that deregulation of HOXB13 may not be restricted to 
the CIMP pathway, as all of the CRC in the study were MSI negative and only three 
samples presented BRAF mutation.  
Protein expression was assessed by western blot in 6 tumors and 5 normal 
mucosas, and by immunohistochemistry in 10 samples (each containing tumor 
and adjacent normal tissue). Remarkably, the results for HOXB13 protein 
expression by western blot showed no association with the respective transcript 
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levels in most of the cases tested. This problem may be related to the sensitivity 
of the protein detection technique. Numerous publications report the use of the 
TRIzol method for nucleic acid extraction, as it is the most commonly used 
method for routine extraction of RNA and DNA (Roos-van Groningen et al., 2004; 
Ali and Alman, 2012; Yamaguchi et al., 2013) In contrast, only few studies report 
the use of this reagent for protein extraction, mainly due to technical difficulties 
in the solubilization of the isolated protein fraction (Butt et al., 2007; Hummon et 
al., 2007; Likhite and Warawdekar, 2011; Simoes et al., 2013). To address this 
issue, we applied some modifications to the TRIzol method which are known to 
improve the quality and yield of protein extracted. Even so, we believe that the 
inconsistency observed between mRNA and protein levels in the samples tested 
relates to the quality of extracted protein. In fact, Likhite et al. (2011) had 
previously reported the limitation of this method for extraction of nuclear protein 
and, since HOXB13 protein is present in the nucleus, it is possible that this 
method was not optimal for nuclear protein extraction of our samples, thereby 
compromising its detection by western blot. 
On the other hand, the association between protein and mRNA levels was 
more evident through immunohistochemistry detection, and the latter seems to 
be a reliable approach to evaluate differences in HOXB13 mRNA expression 
between tumor and normal mucosa greater than 2-fold increase or decrease. This 
would predict that for samples with greater tumor staining relative to normal 
tissue, the expression of HOXB13 would be at least two times higher in tumor 
than in normal tissue. Conversely, samples with greater mucosa staining relative 
to tumor tissue would indicate that, at the mRNA level, the normal tissue would 
express at least two times more HOXB13 than tumor tissue. In the samples 
tested, for FC values between 2 and -2, the results from immunohistochemistry 
showed no differences between tumor and normal tissue. However, in this study 
immunohistochemistry was performed only in 10 samples. Increasing the number 
of samples tested would eventually corroborate these results, but the “cut-off” 
values obtained in the study (2 and -2) could eventually change, since these 
values were stipulated based on the FC values of the few samples tested. 
Additional studies are needed in order to understand the mechanisms and 
molecular consequences behind HOXB13 downregulation in distal tumors, as well 
as its de novo expression in proximal CRC. The possibility that opposite 
molecular changes involving the same gene may both confer selective advantage 
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to CRC cells, depending on their location in the colon, is a very interesting 
scientific question worth to be studied further.  
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VI. CONCLUSIONS  
 
 
Taking into account the results obtained in this study, we can conclude 
that: 
• HOXB13 somatic or germline mutations are not common in colorectal 
cancer patients. Furthermore, 30% of the samples in our study 
exhibited the presence of, at least, one previously described SNP; 
 
• HOXB13 is also expressed in normal proximal colon of patients with 
CRC. However, the expression level is higher in normal tissue from 
distal colon than in proximal colon; 
 
• In distal colon, HOXB13 expression is diminished in tumors compared 
with normal mucosa, whereas in proximal colon there is a tendency for 
the inverse pattern; 
 
• Immunohistochemistry analysis for HOXB13 protein is associated with 
differences in mRNA levels between tumor and normal mucosa higher 
than 2-fold in our samples;                                                                                         
 
• The expression of the HOXB13 gene is not correlated with the 
clinicopathological data of the patients. 
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VII. FUTURE PERSPECTIVES 
 
 
The results obtained in this work are preliminary and further studies are 
necessary in order to support our conclusions.  
Thus, we plan to assess HOXB13 protein expression by Western Blot in the 
rest of the samples from our series, using a different endogenous control, 
specific for nuclear proteins (TBP or histone H4), since HOXB13 is known to be 
expressed in the nucleus. Also, regarding the limitations of nuclear protein 
extraction using the TRIzol method (Likhite and Warawdekar, 2011), other 
extraction methodologies will be tested, and its results compared with the former 
method. 
Also, it would be of interest to further study this gene in the Wnt pathway 
and its relation with the well-known TCF4, since the information regarding this 
subject is limited in CRC. Concurrently, given that HOXB13 is known to be 
downregulated by epigenetic events, the study of these mechanisms might 
provide a clearer insight into the role of this gene in CRC. 
Finally, functional studies of the HOXB13 gene in colon cancer cell lines 
from proximal and distal tumors would allow investigation of the phenotypic 
features of cancer cells when HOXB13 is silenced or expressed “de novo”.  
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